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General principles of vaccination 
 
The immune responses of mammals can be divided into innate and adaptive immunity. Innate 
immunity fights intruding pathogens in a fast, yet non-specific way and can be considered a first line of 
defense. Onset of adaptive immunity instead is delayed, but all responses are directed specifically 
against the respective intruder. A multitude of pathogen-specific cells are created by clonal expansion 
of few, “fitting” pre-cursor cells. And, once infection is resolved, some of these cells survive in the 
body to form immunologic memory ready to fight the same pathogen faster and more efficiently, 
should a second encounter occur. Vaccination takes advantage of this potential of adaptive immunity. 
The principle of vaccination is that exposure to a small sample of a disease-causing microorganism - or 
to a part or portion of it - teaches the immune system to rapidly recognize the menace and to create 
memory that enables the body to fight the real pathogen efficiently during a later encounter. 
Vaccination basically mimics a natural infection without causing disease.  Several are the components 
of host immune responses that are set in motion following vaccination. Important vaccine-induced 
immune effectors are antibodies produced by B lymphocytes. These antibodies are capable to recognize 
and specifically bind to a toxin or a pathogen (or to a portion representative of it)1. Antibody binding 
interferes with pathogen entry into host cells or other important functions. Moreover bound antibodies 
facilitate uptake and elimination of the pathogen by other immune cells. Other important immune 
effectors are cytotoxic CD8+ T lymphocytes (CTL) that may limit the spread of infectious agents by 
recognizing and killing infected cells or by secreting specific antiviral cytokines. The generation and 
maintenance of both B and CD8+ T cell responses is supported by growth factors and signals provided 
by CD4+ T helper (Th) lymphocytes, which are historically subdivided into T helper 1 (Th1) and T 
helper 2 (Th2) subtypes, and more recently also in T helper 17 (Th17). These effector cells are 
controlled by regulatory T cells (Treg) that are involved in maintaining immune tolerance.2 Most of the 
antigens and vaccines trigger both B and T cell responses, and the two responses benefit of their 
interconnection: CD4+ T cells are required for most antibody responses, while antibodies exert 
significant influences on T cell responses to intracellular pathogens3  
Early protective efficacy of a vaccine is often conferred by microorganism-specific antibodies. But just 
triggering a specific antibody response is not sufficient. The quality of such antibody responses, e.g., 
antibody avidity, has been identified as a determining factor of efficacy. Although B lymphocytes 
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represent the specialized lineage in antibody production once differentiated in plasma cells, T cells can 
largely contribute to effective and long-lasting immune responses. In fact, these cells are essential to 
immune memory, and novel vaccine targets have been identified against which T cells are likely to be 
the prime effectors. 
The stimulation of antigen-specific T cell responses requires their activation by specific antigen 
presenting cells (APCs), essentially dendritic cells (DCs), which reside in tissues or patrol through the 
body and are recruited by inflammatory signals to the site of infection. When exposed to pathogens, 
immature DCs will phagocytose and process them proteolytically, so that some pathogen components 
can be loaded on MHC class II molecules. DCs then undergo maturation, modulate specific surface 
receptors and migrate towards secondary lymph nodes, where the trigger of T and B cell responses 
occurs.  
The central role for mature DCs in the activation of vaccine responses reflects their unique ability to 
provide both antigen-specific and co-stimulation signals to T cells. In fact, T cells require at least two 
signals to become fully activated: i) a first antigen-specific signal, is provided through the T cell 
receptor which interacts with the antigen peptide-loaded MHC II molecules on the surface of the APCs; 
ii) a second antigen-unspecific signal, is a co-stimulatory incentive and is provided by the interaction 
between co-stimulatory molecules expressed on the membrane of the APC upon maturation with its 
counterparts on the T cell. APCs can also secrete cytokines that are sensed by the interacting T cell and 
determine its further phenotype (Th1, Th2, Th17). 
The very first requirement to elicit vaccine responses is thus to provide sufficient stimuli through 
vaccine antigens and eventually adjuvants, to trigger an inflammatory reaction that is mediated by cells 
of the innate immune system4. In addition, the antibody response to bacterial polysaccharides is poorly 
affected by adjuvants, IgM represents the major class of antibodies induced and since their immune 
response does not induce memory, it is not boosted by subsequent immunizations. 
These characteristics are due to the fact that, unlike proteins that are T-cell dependent (TD) antigens, 
polysaccharides are T-cell independent (TI) antigens in that they do not require T-cell activation for the 
induction of specific B-cell (antibody) responses. Polysaccharide antigens directly activate 
polysaccharide- specific B cells which differentiate then into plasma cells to produce antibodies, but 
memory B cells are not formed; moreover a pre-existing memory B-cell pool can be depleted by 




Differently from polysaccharides, proteins are TD antigens; following interaction with antigen-
presenting cells (APC) like dendritic cells, macrophages and B-cells, protein antigens are internalized 
and processed into small peptides which are then re-exposed and presented to T lymphocytes in 
association with the major histocompatibility complex (MHC) class II molecules. Interaction with T 
cells induces B cells to differentiate into plasma cells and memory B cells, thus initiating downstream 
adaptive immune responses. Unlike TI antigens, TD antigens are immunogenic early in infancy, the 
immune response induced can be boosted, enhanced by adjuvants, and is characterized by antibody 





Polysaccharides are important virulence factor especially for encapsulated bacteria that present on their 
surface complex carbohydrate structures. Surface polysaccharides have several functions: a) in some 
cases they protect microorganisms from desiccation when they are exposed to the external environment 
-an  example is the hyaluronic capsule of group A Streptococcus, whose adhesive properties help the 
pathogen to invade the host; b) other capsular polysaccharides prevent the activation of the alternate 
complement pathway; c) sometimes they mimic molecules produced by human cells so that the 
pathogen is not recognized as foreign by our immune system (serogroup B meningococcal capsular 
polysaccharide, hyaluronic acid).   
Around 1930s the protective role of antibodies (Abs) induced by pneumococcal polysaccharide started 
to be investigated and in 1945 the first vaccine composed by purified polysaccharide from selected 
pneumococcal serotypes was tested in humans6. 
The research on vaccines development was subsequently slowed down by the introduction of 
antibiotics, however with the emergence of drug resistant strains the development of polysaccharide 
vaccines started again and a number of them have been studied in large clinical studies. Polysaccharide 
vaccines against meningococcus serogroup ACWY, Streptococcus pneumoniae and Haemophilus 
influenzae type be were licensed between the seventies and the eighties.7,8 These bacteria possess 
polysaccharides which are polymers formed by one monosaccharide unit (homopolymers) or more 
complex oligosaccharide repeats (heteropolymers), that can be charged or neutral.  
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Polysaccharide vaccines however did not completely solve the problem of bacterial diseases caused by 
encapsulated microorganisms. Being T-cell independent antigens, one of their main features which 
emerged from clinical trials, was their scarce immunogenicity in children less than two years of age.9,10 
As a consequence, polysaccharide vaccines can be used in adults, but not in infancy and elderly which 
are the most sensitive target populations. 





Glycoconjugate Vaccines  
Glycoconjugate vaccines are among the safest and most efficacious vaccines developed during the last 
30 years. They are a potent tool for prevention of life-threating bacterial infectious disease like 
meningitis and pneumonia.   
The limitation of polysaccharides vaccines has been overcome by covalent conjugation to a carrier 
protein as source of T-cell epitopes. Since 1929 it has been demonstrated by Avery and Goebel that non 
immunogenic sugars after conjugation to a carrier protein become able to induce antibodies in animal 
model.11 However the first application of this concept to a vaccine for human use started only in 1980 
with the development of the first conjugate vaccine against Haemophilus influenzae type b (Hib) that 
was later on licensed vaccine between 1987 and 1990.12,13  
        
Many other glycoconjugate vaccines have been developed against bacterial pathogens such as 
Neisseriae meningitidis, Streptococcus pneumoniae and group B Streptococcus. Today glycoconjugate 
vaccines are among the safest and most efficacious vaccines developed during the last 30 years and 
they are currently used in the immunization schedules of different countries like for example the 





Table 1: Licensed glycoconjugate vaccines. 
 
Chemical conjugation of polysaccharides to protein carriers allows processing of the protein carrier by 
polysaccharide-specific B cells and presentation, on their surface, of the resulting peptides or in 
association with MHC class II. Further interaction with carrier-specific cells then induces a TD 
response already early in life which leads to immunological memory and boosting of the response by 
further doses of the vaccine (Fig. 1). Recently it has been proposed a novel mechanism according to 
which internalization of glycoconjugate and following proteolytic digestions generate glycopeptides 
which are re-exposed by MHCII (Fig. 2) . This model was confirmed by isolation of specific T-cell 
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clones directed to the sugar. This observation proves that although glycoconjugates are safe and 


























Chemistry of glycoconjugate vaccines 
In glycoconjugate vaccines, a covalent linkage between the carbohydrate moiety and the carrier protein 
has to be installed. Approaches based on different chemistry of conjugation, have been so far used. One 
is based on the random chemical activation of the hydroxyl or carboxyl groups of saccharide chain 
followed by covalent binding with Lys residues, onto glutamic or aspartic residues of the carrier protein. 
These are usually the most abundant amino acid residues on protein surface, and the regioselectivity of 
conjugation is hard to achieve. As a consequence these vaccines are effective, but two limitations can 
be found: a) certain degree of batch-to-batch variability in the immunological properties can be present. 
b) it has not been possible to apply precise structure-immunogenicity relationships and use the classic 
medicinal chemistry approach to investigate vaccine candidates.  
 
 
Recently different methods to target specifically some residues for bioconjugation are emerging. In 
general, three main approaches for site-selective incorporation of carbohydrates onto proteins can be 
described21 (1) chemical ligation-based strategies, which rely on the reaction of two unprotected 
peptide moieties bearing a C-terminal thioester and a N-terminal cysteine; (2) chemoenzymatic 
transformations (“remodeling”) of glycoproteins with endoglycosidases or other glycan processing 
enzymes; (3) site selective conjugation to natural and unnatural amino acid residues, such as 
homoallylglycine, S-allylcysteine or Se-allylselenocysteine, azidoalanine presenting chemical groups, 
which can react under the mild conditions present in biological systems (aqueous media, mild pH, and 
temperature). Combination of oligosaccharide synthesis and novel site specific methods may enable an 
accurate antigen design and a more precise correlation between the glycoconjugate structure and the 
immunological properties.22  
 
 
Among these methods, targeting tyrosine residues by chemical manipulations has appeared very 
attractive. Proteins usually present much less tyrosine than lysine, glutamate or aspartate residues, and 
they are also often buried.  The accessible tyrosine residues on protein surface are usually few, thus the 
regioselectivity of conjugation can be expected. Recently a reliable tyrosine-selective conjugation 
method via triazolidinone derivatives in tris buffer has been developed.22 The method enabled the 
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insertion of alkyne-containing bifunctional linkers onto the tyrosine residues of the genetically 
detoxified diphtheria toxin CRM197. The subsequent condensation of a synthetic β-glucan by Cu(I) 
catalyzed azide-alkyne [3+2] cycloaddition (CuAAC)23,24  enabled the creation of  an anti-
candidiasis vaccine.25	   
This strategy was proven a powerful method to obtain a robust structure-immunogenicity relationship 
from glycoconjugates with defined sugars at predetermined sites. In addition, it has been shown that the 
triazole generated by the cycloaddition is either moderately or non-immunogenic and does not affect 
the anti-carbohydrate response. Therefore, this conjugation approach appears a robust approach for 




























Streptococcus agalactiae, also known as group B Streptococcus (GBS), is one of the major causes of 
sepsis, pneumonia, and meningitis in neonatal and infants in the first three months after birth.26 It is a 
Gram positive beta-hemolytic coccus which appears in pairs (Fig.6) or chains27, that colonizes the 
urogenital and gastrointestinal tracts of more than 30% of the healthy population and, in particular, the 
vagina of 25-40% of healthy women.28-30 
 
Fig.6 Immunogold Electron Microscopy of GBS strain CJB111(Rosini, Rinaudo et al. 2006). 
 
It was classified for the first time in 1930 by R. Lancefield and R. Hare during a serological 
differentiation study on human isolates and other groups of hemolytic streptococci.31 It is included in 
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the group B of “Lancefield System”, where Streptococci are identified with alphabetical letters from A 
to O, based on capsular polysaccharide antigens and groups A, B and D are the most dangerous32. GBS 
clinical isolates are also classified into ten serotypes, according to the chemical nature of capsular 
polysaccharides (PS): Ia, Ib, II, III, IV, V, VI, VII, VIII and IX.33-35 However around 8-14% of the 
clinical isolates in the Europe and USA are non-typeable strains because cannot be distinguished on the 
basis of PS antigenicity. All GBS serotypes contain, in different combinations, these carbohydrates: 




Fig. 7 Chemical structures of isolated GBS serotypes 
 
Streptococcus agalactiae is known as the most frequent cause of sepsis, pneumonia and meningitis in 
neonates within first months from birth.36, 37 It is an etiologic agent also in adults, in particular elderly 
persons, immunocompromised, diabetics, and patients affected by others chronic pathology of liver and 
kidney. In the cellular hyper-trophism of vaginal epithelium, where it can adheres despite low values of 
pH38, it forms a permanent colonization in more than 40% of women. During pregnancy, the uro-
genital tract colonization is cause of severe infections/year, leading to chorioamnionitis, endometrial 
tenderness, tachycardia, cystitis and fever which make necessary antibiotic therapies also after delivery. 
GBS can also be cause of intrauterine death, aborts, prelabor rupture of the membranes, with preterm 
labor/delivery, causing the exposure of 90% of premature neonates to infection. In most cases infection 
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is transferred vertically from asymptomatic mothers and, every year, only for US, 8000-12000 infected 
babies and 2000 deaths are recorded.  Infection appears in uterus or at delivery for contact of throat, 
ear, nostril, umbilicus and respiratory ways with amniotic liquid or infected vaginal fluids. After the 
aspiration/ingestion of bacteria, neonatal lungs become the starting focus of infection. From here it can 





Fig.8 Stages of neonatal group B streptococcal (GBS) infection (Doran and Nizet 2004).   
 
Neonatal disease can occur in two different forms: the Early-Onset Disease (EOD) and the Late-
Onset Disease (LOD).  
 
EOD occurs during the first seven days of life, with the vast majority of cases (approximately 90%) 
present during the first 24 hours of life.39 Neonates with EOD present respiratory disease (54%), sepsis 
without focus (27%) and meningitis (15%).40 Risk factors include: GBS bacteriuria during pregnancy; 
gestational age less than 37 weeks; previous infant with invasive GBS disease; preterm labor/delivery; 
prelabor rupture of membranes; birth weight less than 2500g; black race and teenage mothers. 
 
LOD occurs beyond seven days of life and can develop up to three months of age. In 50% of the cases 
it has a maternal origin. Neonates with LOD present sepsis (46%), meningitis (37%), urinary infection 
(7%), osteoarthritis (6%), respiratory disease (4%) and cellulitis (4%). Over 20% of survivors of GBS 
meningitis have permanent sequelae, including hearing loss, mental retardation, cortical blindness and 









Tab. 2 Neonatal manifestation of group B streptococcal disease (Shet and Ferrieri 2004). 




First week of life (usually 
within the first 24 h) 
 
One week to 3 months of 
age 






Incidence of prematury Increased No change 
Maternal obstetrical 
complication 
Frequent (70%) Uncommon 
Transmission Vertical: acquired in utero 
or intrapartum 
Usually horizontal 
transmission: can also be 
intrapartum 
Predominant serotypes* Ia, III, V III, Ia, V 
*In descending order of prevalence  
 
Risk factors include non-white race and preterm birth, but most of time it is an horizontal transmission, 
after contact with sanitary staff or colonized mothers. LOD is basically due to serotype III strain, with 
an incidence until 60% depending on the geographic area. Studies performed on non-pregnant adults 
with GBS associated invasive disease revealed that GBS serotypes Ia, III and V accounted for more 
than two-third of cases. More than 25% of the subjects had invasive GBS disease caused by type V 













     Table 3 Serotype distribution of group B streptococcal isolates from non-pregnant  













The clinical manifestations of GBS infection in elderly adults are: skin and soft-tissue infections and in 
these cases, cellulites is the most frequent clinical manifestation, urinary tract infections (bacteremic 
urinary tract infections account for 33.4% of the cases in adults >70 years of age), pneumoniae (only in 
older debilitated adults), bacteremia with no identified focus (in the 15% of non-pregnant adults 
affected by GBS invasive diseases), arthritis, osteomyelitis, meningitis (in only 2% of non-pregnant 
adults with GBS invasive disease) and endocarditis. 
 
GBS Vaccine 
Early in 1930s Rebecca Lancefield et al. demonstrated that polyclonal antibodies from rabbit sera, able 
to recognize PS epitopes, conferred protection against GBS infection in animal models. During the last 
two decades, plain GBS polysaccharides have been extensively studied as vaccines in preclinical and 
human clinical studies. However, the first human clinical trials conducted in the 1980s showed that the 
purified native PS from serotype III was not sufficient to induce an robust IgG response in adults  and 
insignificant in neonates.  
Subsequently, conjugation of PSs to immunogenic proteins, such as tetanus toxoid (TT) and mutated 
diphtheria toxoid (CRM197),41, 42 was shown to dramatically increase the immune response in children, 
GBS serotype 
N° (%) of subjects 
(n=589) 
Ia 143 (24.3) 
Ib 72 (12.2) 
II 70 (11.9) 
III 97 (16.5) 
IV 2 (0.3) 
V 162 (27.5) 
VI 0 
VII 0 
VIII 1 (0.2) 
Non-typeable 42 (7.1) 
20	  
	  
eliciting the differentiation of memory cells associated to a long term protection. Following these 
findings, PS-TT conjugate vaccines based on nine GBS serotypes were produced and tested pre-
clinically.41 These studies, carried out in animal models, showed that conjugate antigens were able to 
induce functional PS-specific IgG that, in presence of complement, stimulate in vitro the opsonization 
and killing of GBS by human peripheral blood leukocytes. This success constituted the rationale to 
proceed with the clinical studies in human. Further studies demonstrated that glycoconjugate vaccines 
constituted by serotypes Ia, Ib, II, III, and V PS linked to TT were safe, well-tolerated and highly 
immunogenic in human adults,42 but cross-protection between serotypes was still lacking. Therefore a 
multivalent vaccine was required in order to obtain a broad coverage of the vaccine against the 
prevalent circulating GBS serotypes. A tetravalent combination of PS –TT conjugates (serotypes Ia, Ib, 
II, and III) was successfully tested in a mouse model and further human trials were performed using the 
combination of two PS TT-conjugates (serotypes II and III). Results showed that the combination had 
the same immunogenicity and reactogenicity of each monovalent PS vaccine.42  
However, although recent epidemiological studies43 suggest that a tetravalent combination of serotypes 
Ia, Ib, III and V would be sufficient to achieve a coverage against the majority of GBS strains 
circulating in Europe and North America, there are other geographical areas where such combination 
would be not be effective owing to a different serotypes distribution (i.e. VI and VIII, predominant in 
Japan). Moreover, the PS-conjugate vaccine would not protect against all the non-typeable isolates.  
An additional obstacle to the licensure of vaccine against GBS is the difficulty of conducting clinical 
efficacy trials in human: large sample size would be required, but the use of IAP reduces the incidence 
of neonatal disease. A possible solution to overcome this difficulty came from the studies of Feng-Ying 
C. Lin and coworkers who carried out a prospective way to estimate the maternal GBS-PSs antibody 
levels needed to give protection to neonates from EOD. The amount of maternal antibodies against 
GBS-PSIa was measured by ELISA in 45 case patients (mothers whose neonates developed EOD) and 
319 controls (mothers of neonates colonized by GBS-PSIa but without EOD). Distribution of maternal 
antibody concentrations showed that the probability of developing EOD declined with increasing 
maternal levels of anti-PSIa IgG.44 This work demonstrated that it is possible to define thresholds of 
anti-GBS PSIa specific IgG levels in the mothers which are predictive for the protection of newborns.  
More recently, thresholds have also been set for the levels of maternal anti GBS-PSIII IgGs required to 
protect newborns from EOD caused by GBS serotype III.45 The results of Feng-Ying C. Lin suggested 
that complex clinical trials required for a GBS vaccine registration, might be replaced with an in vitro 




Pilus protein-based vaccine 
 
The protection induced by a polysaccharide based is limited to strains expressing the same CPSs 
included in the vaccine formulation. For this reason the development of a cross-protective protein 
vaccine is another relevant option.  In order to develop a serotype independent universal GBS vaccine, 
several efforts have been focused on the identification of highly protective protein antigens. Unlike 
CPS antigens, proteins antigens are able to induce protective T-cell-dependent antibody responses and 
long-lasting immunity and conjugation to carrier molecules (i.e. TT or CRM197) is not necessary. Since 
antibodies directed against surface antigens can interfere with bacterial virulence factors and can 
promote complement dependent opsonophagocytosis, they are considered excellent vaccine candidates.  
Before 2005, only a few GBS protein antigens have been identified as potential vaccine candidates; 
these include Rib, the alpha and beta subunits of the C protein, Sip and the C5a peptidase proteins. 
However, these proteins, with the exception of C5a peptidase and Sip, are either not expressed on all 
strains or are highly variable in different isolates.46 The C-protein complex was able to induce passive 
protection against GBS infections in an animal model.47 Further studies also showed that the C-protein 
complex could be one of the factors that confer resistance to opsonization.48 Rib is a surface protein 
with a similar structure and sequence to the alpha subunit of the C protein and it is also able to induce 
protective immunity.49 Unfortunately, the alpha subunit of the C protein is present in the genome of 
only approximately 50% of clinical, while Rib is present in the genome of all serotype III strains, but 
not in other serotypes. Moreover, both these proteins (the alpha subunit of the C protein and Rib) 
contain repeated sequences that show strain-to-strain variations and that can affect their 
immunogenicity. Sip (surface immunogenic protein) is a surface GBS protein that was identified after 
immunological screening of a genomic library. Sip has been identified in GBS strains of every serotype 
and the sip gene is highly conserved among GBS isolates.50 The protection conferred by the Sip protein 
was determined by a mouse neonatal infection model. Newborn mice were protected against infections 
of GBS strains of serotypes Ia, Ib, II, III, and V.50 Furthermore, it has been observed that sera collected 
from pregnant women and their healthy newborns have Sip antibodies. The C5a peptidase is a serine-
protease localized on the surface that inactivates the human C5a a factor produced during complement 
activation. C5a is highly conserved surface-bound protein that is expressed on the surface of all 
serotypes of both group A  (GAS) and group B streptococcus.51 The GBS C5a peptidase (ScpB) is 98% 
identical in sequence to that expressed by GAS.  It has been shown that C5a peptidase is a protective 
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antigen, and could be also used as a carrier protein for type III polysaccharide vaccine. Up to 1995, 
when the first complete microbial genome sequences became available, vaccines has been classically 
developed by isolating, inactivating and injecting the cause of the infection. These traditional 
approaches are time-consuming and expensive. In 1995, a new era named “the genomic era”, began 
chancing completely the approach for vaccine development. The microbial genome sequencing,52 
provided a new impulse to the vaccinology field.  A new approach named Reverse Vaccinology, based 
on integration of several techniques such as genomics, bioinformatics, and molecular biology.53 
 
 
Fig. 9 Comparison between conventional approach and Reverse Vaccinology 
(Johri, Paoletti et al. 2006).  
 
Unlike the conventional vaccine approaches, the reverse vaccinology, permits the identification of less 
common, low expressed and/or not expressed in vitro antigens and can be applied also on non-
cultivable microorganisms. On the other hand, it can be applied only on the discovery of proteins 
antigens but not to others antigens such as lipopolysaccharides and glycolipids.54 Application of the 
reverse vaccinology approach to the development of vaccine against GBS commenced from the 
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sequencing of the complete genome of a virulent GBS strain (2603v/r, serotype V). However, a 
Comparative Genome Hybridization (CGH) analysis showed that the genetic variability within the 
GBS isolates was too high and represented a limit for the identification of vaccine candidates. From 
this analysis it was evident the need to include genome sequences of more serotypes for the selection of 
protein antigens. In order to study the genome variability in GBS, Tettelin and coworkers sequenced 
the genome of 6 GBS strains which represent the most disease-causing serotypes (serotype Ia strains 
A909 and 515, type Ib strain H36B, type II strain 18RS21, type III strain COH1 and type V strain 
CJB111). By a comparative analysis of all available genomes, the new sequenced genomes plus the 
two already published genomes, it was possible to identify two subgenomes: the “core genome” and the 
“variable genome”, together defined as “pan genome”.55 The “core genome” includes genes present in 
all the strains and is around the 80% of each genome and contains all genes necessary for the basic 
biology of the bacteria, on the other hand, the “variable genome” is responsible for strain diversity and 
represents the part of genes that is dispensable and unique to each strain.  
The surface availability of the antigens to antibody recognition is a prerequisite for a good protective 
immune response. Maione and coworkers searched within the GBS pangenome for the genes coding 
for putative surface-associated and secreted proteins. Using this approach around 589 putative surface 
proteins were selected, among them 396 belonged to the core genome and 193 were variable genes. 
The proteins containing more than three trans-membrane domains were excluded because of the 
difficulties predicted for their production in E. Coli.  By using a high-throughput cloning and 
expression approach, 312 of the selected GBS genes were successfully expressed in E. coli. Each of the 
genes was cloned with sequences coding for either an N-terminal 6XHistidine Tag or for a C-terminal 
glutathione S-transferasetag and the expressed proteins were purified by affinity chromatography. All 
the 312 purified recombinant GBS antigens were tested by an active maternal immunization/neonatal 
pup challenge mouse model of GBS infection. Briefly, the antigens were used to immunize female 
mice with a three dose immunization schedule. After the last immunization, mice were mated and their 
pups were challenged, within 48 h after birth, with a lethal dose of GBS. The survival of the neonates 
was monitored for 3 days and immune sera were collected for in vitro analysis. Immunoblot assays 
were used for the identification of the natural protein in GBS total protein extracts, while flow 
cytometry assays were carried out to confirm the surface exposure of the antigens. From this first 
systematic screening four antigens were identified as capable of significantly increasing the survival 
rate among challenged infant mice. When the four antigens were mixed and administered 
simultaneously, an almost universal protection was achieved against challenge model using a panel of 
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strains comprehensive of the most pathogenic GBS serotypes. In particular, the levels of protection 
reached were similar to those achieved using the polysaccharides-based vaccines. Only one (SAG0032) 
of these four antigens was part of the “core genome”, and this protein was the already described Sip 
protein. The other three antigens named GBS67 (SAG1408), GBS80 (SAG0645) and GBS104 
(SAG0649) were present in the variable portion of the subgenome. The major outcome of this study 
was that the combination of these antigens, each effective against overlapping populations of isolates, 
was able to confer broad serotype-independent protection. Characterization studies revealed that three 
of these antigens (GBS67, GBS80 and GBS104) were component of pilus-like structure  (Fig. 10). 56  
 
 
Fig.10  Examples of pilus-like structures in Gram-negative and Gram-positive bacteria. Electron micrographs of pili in 
Gram-negative organisms: E. coli (A) and Salmonella enterica (B). Electron microscopy of two different types of pili in 
Gram-positive bacteria: fimbrie in Streptococcus salivarius (C) and pili in Streptococcus agalactiae (D) (Rosini, Rinaudo et 
al. 2006).  
 
In the 1970s Brinton et al had already showed that pilus-based vaccines induced protection in humans 
against gonococcus and against enterotoxigenic E.coli.57 Genome sequence analysis of GBS revealed 
three independent loci named Pilus Island 1 (PI-1) and Pilus Island 2a and 2b (PI-2a, PI-2b) which 
encode structurally distinct pilus types. In fact, Pilus Island 2b (PI-2b) is an allelic variant of PI-2a that, 





Fig.11 Schematic representation of GBS pilus island regions (A. PilusIsland 1; B. PilusIsland 2)  
(Rosini, Rinaudo et al. 2006). 
 
The overall gene corresponds to the major pilus subunit (backbone protein [BP]) and the two ancillary 
proteins (AP1 and AP2). BP and AP1 were shown to elicit opsonophagocytic antibodies able to protect 
mice in the active maternal immunization model. From the studies of Maione et al. and later of Rosini 
et al., it was demonstrated that at least 2 of the 3 pilus structural components, the BP and the AP1, 
encoded by the PI-1 (respectively GBS80 and GBS104) and by the PI-2a (respectively GBS59 and 
GBS67) were able to induce protective immunity against GBS infection in mice. More recently, 
Margarit and coworkers showed that all GBS strains carry at least one of the three Pilus Islands, thus a 
vaccine containing one component of each pilus is capable of providing a high level of protection 




Fig.12 Distribution of pilus islands among 289 GBS isolates grouped by disease type (A) and capsular 
polysaccharide serotype (B). NT = non-typeable(Margarit, Rinaudo et al. 2009). 
 
Two backbone proteins of PI-1 (GBS80) and PI-2b (GBS1523) and the ancillary protein of PI-2a 
(GBS67) were identified as potential antigens to include in a final GBS vaccine formulation, in order to 
increase the coverage of a polysaccharide-based vaccine.58 
 
Clostridium difficile 
Clostridium difficile is a gram-positive anaerobic bacterium able to infect either humans or animals and 
commonly found in the environment. It was isolated for the first time in 1935 from the intestinal flora 
of neonates and was initially considered a normal non-pathogenic resident of the gut. Only in 1970s 
was C. difficile identified as one of the agents responsible for antibiotic- related diarrhea and 
pseudomembranous colitis.59-63  
C. difficile infection (CDI) has grown tremendously since 1978, and over the last decade, the incidence 
and severity of CDI has increased significantly and affected new patient groups. Today, the disease 
represents a major social and economic burden. Since 2005, CDI has been increasingly reported among 
young, healthy individuals residing in the community. An estimated 20% to 28% of CDI is community 
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associated with an incidence of 20 to 50 cases per 100,000 populations in the United States, Sweden 
and England. At the moment, there is no vaccine against C. difficile, despite the increase in the 
incidence of the disease observed in the last decades. The efficacy of anti-CDI vaccines based on the 
administration of formalin inactivated toxoids A and B has been described for over 3 decades. This 
vaccine consists of formalin-detoxified toxins A and B obtained by purification from culture of VPI 
10463, which is a hyper-productive strain for both toxins. The use of toxoid-based vaccines in humans 
has been limited for a long time, despite several studies in animal models having demonstrated the 
importance of toxin immunity in preventing the lethal outcome of CDI. To overcome the safety issues 
associated with the large-scale production of toxoids, such as exposure to toxins and spores, Donald 
and colleagues have recently proposed a novel recombinant toxoid-based candidate vaccine consisting 
of genetically modified TcdA and B produced in a non-sporulating strain of C. difficile lacking the 
genes for the native toxins. Although site-directed mutations abrogate cytotoxicity linked to the 
glucosyl- transferase activity of the toxins, a residual toxicity was observed which has been prevented 
by formalin treatment. This genetically and chemically detoxified recombinant vaccine induced 
functional antibodies in the hamster model and conferred a partial protection to lethality. A phase I 
clinical trial of this vaccine is currently ongoing. Polysaccharides coating the surface of bacterial 
pathogens represent an optimal target for eliciting carbohydrate specific antibodies. Glycans are T cell 
independent antigens, but they can be turned into molecules able to evoke a T cell memory response 
following conjugation to a carrier protein. This strategy has found application in the prevention of 
many deadly infectious diseases. Consequently, great attention has been directed in the recent years to 
the structural analysis of polysaccharides on the surface of C. difficile with the result of identifying 3 
glycan structures, named PSI, PSII, and PSIII. Following the discovery of PSII, it was not clear 
whether PSII was part of a capsule or a surface glycoprotein, or released to the external surface of the 
bacterium. Antibodies against the conjugated PSII detected the polysaccharide at the surface of the 
bacterial vegetative cells, thus confirming this molecule as a target for a carbohydrate based vaccine. 
However the sugar coating was not as thick and uniformly distributed as expected for a capsule. 
Therefore, it can be hypothesized that PSII is expressed by the bacterium either as cell wall-linked 










Outline of the thesis 
In the last ten years a considerable effort in developing more effective vaccines for the prevention of 
bacterial infectious diseases has been made. Conjugation to protein carrier is a well-established 
approach to trigger a T-cell-dependent response against poorly immunogenic microbial carbohydrates. 
During my PhD I investigated the use of proteins, which are antigens per se, as carrier for carbohydrate 
antigens. We have explored the possibilities of using protein which are 1) bacterial surface antigens or 
2) toxins. 
In this first case, we have employed GBS pili proteins, which by the “reverse vaccinology” approach 
have been demonstrated important structures for bacterial adhesion and invasion, and also powerful 
antigen against GBS infections. In this context we exploited GBS80 pilus protein as antigen and carrier 
for GBS type II polysaccharide (PSII) in order to broaden the vaccine coverage. Site-selective 
bioconjugation methods represent potent tools to generate novel therapeutic proteins, chemical biology 
probes, or to engineer targeted delivery systems and bionanomaterials. While classic procedures for 
conjugation relies on the random reaction of the with the carrier protein, new efficient methods for site 
selective conjugation of glycans are emerging. These methods may represent important tools to 
investigate the effect of the conjugation sites on the immunological properties of glycoconjugate 
vaccines. Hence, the impact of coupling site on the protective epitopes of GBS80 has been evaluated. 
Accordingly, as first step we developed a method for efficient tyrosine-directed coupling of small 
glycans and large polysaccharides to proteins via copper-free click chemistry. Then glycoconjugates 
from GBS pili proteins and polysaccharides were prepared using a classic random conjugation strategy 
and the novel method for tyrosine-directed ligation. The capability to elicit anti-carbohydrate and anti-
protein antibody titers that induce opsonophagocytic killing of strains expressing exclusively PSII, or 
GBS80 was evaluated. In addition, survival of new born mice against GBS infection following 
vaccination of the mothers with the different glycoconjugates was compared.  
In another study of my PhD we evaluated the efficacy, in naive mice model, of PSII glycoconjugates 
where recombinant toxins A and B fragments (TcdA_B2 and TcdB_GT respectively) were used as 
carriers. Both glycoconjugates were evaluated for the proficiency at inducing anti-PSII IgG titers and 
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Recombinant Clostridium difficile toxin fragments as carrier protein for PSII 
surface polysaccharide preserve their neutralizing activity 
Maria R. Romano, Rosanna Leuzzi, Emilia Cappelletti , Marta Tontini, Alberto Nilo, Daniela Proietti, 
Francesco Berti, Paolo Costantino, Roberto Adamo and Maria Scarselli 
1. Introduction 
Clostridium difficile is a Gram-positive, spore-forming and toxin-producing anaerobic gastrointestinal 
pathogen that is the major cause of antibiotic-associated colitis. C. difficile has been isolated from 
several domestic and nondomestic animal species, and has been associated with diarrhea in horses, 
pigs, dogs and cats. In humans, C. difficile associated diarrhea (CDAD) is the most commonly 
diagnosed cause of hospital-associated and antimicrobial-associated diarrhea.1  
C. difficile infection (CDI) has grown tremendously since 1978, and over the last decade, the incidence 
and severity of CDI has increased significantly and affected new patient groups. Today, the disease 
represents a major social and economic burden.2 Since 2005, CDI has been increasingly reported 
among young, healthy individuals residing in the community. An estimated 20% to 28% of CDI is 
community associated with an incidence of 20 to 50 cases per 100 000 population in the United States, 
Sweden and England.3  
At the moment, there is no vaccine against C. difficile, despite the increase in the incidence of the 
disease observed in the last decades.4-5  
The virulence of C. difficile is conferred primarily by 2 large exotoxins, toxins A and B, and there is 
evidence that protection against severe CDI is mediated by systemic antibodies to TcdA and TcdB.6-8 
Both toxins present three distinct functional domains: an N-terminal enzymatic domain consisting of 
glucosyl-transferase (GT) and cysteine protease (CP) moieties, a central translocation (T) domain that 
mediates import into host cells and a C-terminal receptor binding domain (RBD) with 38 tandem 
repeats.9  
Although a number of studies have demonstrated that anti-toxin circulating antibodies are effective in 
the treatment of severe CDI,10-11 supporting the key role of toxin immunity in preventing the lethal 
outcome of this infection, the use of toxoid-based vaccines in humans has been limited for a long time. 
Recently, preparations of formaldehyde-inactivated toxoid from C. difficile culture supernatants have 
been able to confer protective immunity in clinical trials.11-14 
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To overcome the safety issues potentially associated to the large-scale production of toxoids, such as 
exposure to toxins and spores, the use of recombinant proteins has been proposed as an attractive 
alternative for development of vaccines against CDAD.15 Several studies have demonstrated the ability 
of recombinant toxin fragments to induce robust immunity against lethal challenge with C. difficile. In 
particular, TcdA and TcdB RBDs, cloned and purified from a variety of hosts, have been proven to 
induce both systemic and mucosal neutralizing antibodies in animal models.16-18 Our group has recently 
shown that co-administration of a cell binding domain fragment of TcdA (TcdA_B1) and the 
glucosyltransferase moiety of TcdB (TcdB_GT) can induce systemic IgGs, neutralizing both toxins and 
protecting vaccinated animals from death in hamster animal model of lethal infection. The presence of 
anti-TcdA and TcdB antibodies was assessed in gut contents, suggesting that systemic vaccination with 
this pair of recombinant polypeptides can limit the disease caused by toxin production during C. 
difficile infection.19 However, anti-toxins antibodies elicited by toxin fragments are not able to limit the 
level of bacterial load in the gut.20 
Recently it has been shown that C. difficile vegetative cells express three highly complex 
polysaccharides on their cell surface, named PSI, PSII and PSIII. Among those three carbohydrates, 
PSII has been found to be the more abundantly expressed by the hypervirulent rybotype O27.21 The 
PSII is a polysaccharide composed of a hexaglycosyl phosphate repeating unit [-6)-β-D-Glcp-(1-3)-β-
D-GalpNAc-(1-4)-α-D-Glcp-(1-4)-[β-D-Glcp-(1-3)]-β-D-GalpNAc-(1-3)-α-D-Manp-(1-P].22 
We have previously employed the high-resolution magic angle spinning (HR-MAS) NMR on 
vegetative whole cells from a collection of clinical isolates and have detected PSII on the surface of 
different rybotypes, such as  001, 018,  027, 078 and 126.23 The list of isolates analyzed by this 
technique has been further updated, detecting PSII in a number of clinical and environmental isolates, 
including strain 630.24 Therefore, PSII is as a surface antigen conserved among the most common 
strains and can represent a relevant target for the development of a carbohydrate-based vaccine. 
In confocal microscopy, examination of vegetative cells using anti-PSII antibodies revealed that PSII 
does not appear as a typical thick and even bacterial capsule; then it can be hypothesized that the 
polysaccharide is present either as cell wall-linked polysaccharide not bound to peptidoglycan or as a 
conjugate with lipoteichoic acids.21, 24 
Interestingly, strain 630 and the hypervirulent strain R20291 can form in vitro structured biofilms, 
where the presence of PSII could be detected by antibodies against the phosphorylated hexaglycosyl 
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repeating unit.25 This suggests that extracellular PSII could play a role in determining the biofilm's 
architecture of C. difficile as component of extracellular matrix. 
Glycans are T cell independent antigens, but they can be turned into molecules able to evoke a T cell 
memory response following conjugation to a carrier protein.26 Anti unconjugated PSII IgM antibodies 
have been generated in pregnant pigs vaccinated with a non-adjuvanted PSII containing an average of 6 
repeating units.27 PSII, after conjugation to CRM197 (non-toxic mutant of diphtheria toxin),28 a carrier 
protein widely used for the manufacturing of glycoconjugate vaccines,29 was formulated with the 
adjuvant MF59 and tested in Balb/C mice, inducing high levels of specific anti carbohydrate IgG, a 
class of antibodies which is generally relevant to induce protection against the sugar coated 
pathogens.23 Therefore, conjugation of PSII to the carrier protein could ensure, as expected, the IgM-to-
IgG switch. Noteworthy, glycoarray analysis has demonstrated that specific IgA antibodies in the stool 
of patients infected with C. difficile can recognize the nonphosphorylated PSII hexasaccharide hapten, 
suggesting that under exposure to PSII the human immune system may furnish a mucosal response 
against carbohydrate epitopes from PSII.30  
The co-administration of multiple C. difficile antigens, by using recombinant toxin fragments 
conjugated to PSII could have the potential to prevent colonization and protect against C. difficile 
disease. We envisaged in conjugation of PSII to toxins as a strategy to ensure co-delivery of the two 
antigens, while using the toxin as carrier protein for the polysaccharide. With this aim, we have 
evaluated the immunological response of PSII-toxin based glycoconjugates in mouse, investigating the 
possible double role of the two TcdA_B2 and TcdB_GT fragments, as carrier protein for the PSII 
polysaccharide and antigens able to elicit antibodies with toxin neutralizing activity.  
 
2. Results and Discussion 
2.1. PSII-toxins conjugate  
PSII is composed of hexaglycosyl repeating units hold together by phosphodiester bonds,22 and the 
assigned structure has been confirmed by synthesis of the non-reducing end terminal phosphorylated 
repeating unit.31  
Pure PSII with an average degree of polymerization (avDP) of 15, obtained from fermentation of the 
R20291 strain (Stoke Mandeville -ribotype 027) as previously reported,23 was conjugated to the two C. 
difficile recombinant fragments derived from TcdA and TcdB after chemical modification of the 
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mannose sugar of the repeating unit at the reducing end. PSII was first reduced with NaBH4 and then 
oxidized with sodium periodate to introduce an aldehyde group useful for the coupling to the lysine 
residues of the protein by reductive amination23 (Fig. 1). The occurrence of complete conjugation was 
assessed by SDS-PAGE, and confirmed by the formation of a broad smear and the concomitant 
disappearance of the narrow band of the proteins (Fig. 2). Subsequently, the glycoconjugates were 
purified by size exclusion chromatography to remove unbound saccharide and analyzed for their 
protein content and in terms of total and free saccharide by HPAEC-PAD HPLC as described in 
literature.23  
Table 1 summarizes the physico-chemical characterization of the purified glycoconjugates in term of 
total and free saccharide and protein content, compared to the PSII-CRM197 conjugate of which the 
preparation and the characterization were previously reported.23 Notably, the degrees of glycosylation, 
ranging from 0.2 to 0.3 (w/w), was comparable for both the products.  
 










Figure 2. SDS-Page of PSII-Toxin Conjugates 1. TcdA_B2 fragment protein; 2. PSII-TcdA_B2 
conjugate, 3. TcdB_GT fragment protein; PSII-TcdB_GT conjugate. 
 
Table 1. Characteristics of PSII Conjugates. 





PSII-TcdA_B2 15 7.7 0.28 
PSII-TcdB_GT 15 22.7 0.33 
PSII-CRM197* 21 11.2 0.24 
*characterization previously described23 
 
2.2. Immunological Evaluation of PSII-toxins conjugates 
To assess the ability of conjugates to induce anti-PSII antibodies, groups of 8 female BALB/c mice 
were intraperitoneally immunized three times with 2.5 µg carbohydrate based doses of conjugates, at 
three week-interval between the first and the second dose and two week-interval from the second and 
the third dose. The conjugates were formulated with the adjuvant MF59, an oil in water emulsion 
frequently used for seasonal flu vaccination.32 Adjuvant alone in phosphate buffer (PBS) was used as a 
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polysaccharide immune response,23 and the TcdA_B2 and TcdB_GT fragment proteins already shown 
to be highly immunogenic,19 were used as a positive control. 
Sera obtained after two weeks from the third dose (post 3 sera) were analyzed by ELISA for their 
content of anti-PSII and anti-Toxin IgGs. Additionally, the functionality of the anti-Toxin antibodies 
was investigated in vitro to assess the capacity to neutralize the cytotoxicity of TcdA and TcdB. 
The PSII-TcdB_GT conjugate was highly immunogenic, eliciting anti-PSII IgG titres comparable to 
those obtained with the PSII-CRM197 conjugate. Conversely, PSII-TcdA_B2 conjugate induced an anti-
polysaccharide response significantly lower than the CRM197 conjugate (p 0.006), where IgGs against 
PSII were induced in three mice only (Fig. 3). These results evidenced a better capability of the 





Figure 3. Anti-PSII IgG levels detected in individual post 3 sera of BALB/c mice; each dot represents 
single mouse sera; vertical bars indicate geometric mean titers of each group with 95% statistical 











The antibodies response to the TcdA_B2 and TcdB_GT fragment proteins as carrier was measured and 
compared with the IgG titers obtained with unconjugated TcdA_B2 and TcdB_GT fragment proteins. 
As shown in Tab. 2, both conjugated toxin fragments evoked a robust anti protein response. However, 
unconjugated TcdA_B2 elicited significantly higher anti toxin fragment antibodies in comparison to the 
corresponding PSII conjugate (p 0.002), while TcdB_GT induced IgGs levels comparable to the 
conjugated form. 
 
Table 2. IgG levels detected in individual post 3 sera of BALB/c mice against TcdA_B2 and 
TcdB_GT coating. 
 
 IgG Titer (GMT95% CI) 
PBS 2 
TcdA_B2 fragment protein 1,024,000 (374,868-4,023,000) 
PSII-TcdA_B2 conjugate 51,499 (28,721-109,279) 
TcdB_GT fragment protein 206,317 (47,610-400,390) 
PSII-TcdB_GT conjugate 106,936 (69,489-174,511) 
PSII-CRM197 2 
 
Next, the functionality of the antibodies was verified by the in vitro toxin neutralization assay of pooled 
sera from mice immunized with the conjugates. Remarkably, as shown in Fig. 4, both PSII conjugates 
elicited  toxin neutralizing activity comparable to that induced by their respective protein carrier in 
unconjugated form, indicating that chemical conjugation did not alter the critical epitopes of 
recombinant toxin A and B fragments. As previously demonstrated,19 TcdA_B2 and TcdB_GT induce 
neutralizing antibodies only against the cognate toxin (data not shown), suggesting that vaccination 
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should include combinations of fragments derived from each toxin to achieve the concurrent 

















































Figure 4. Neutralization titers of sera from mice immunized with toxin A and B fragments, either alone 
or conjugated to PSII, in the presence of MF59 adjuvant. Titers were defined as the reciprocal of the 
highest dilution able to inhibit 100% rounding in IMR-90 human fibroblasts treated with 1 CTU100 of 
toxin A (white column) or B (grey column). Pre-immune sera were used as negative controls. Values 
reported in the table represent the mean dilution from 3-5 independent experiments. 
 
 
3. Experimental Section  
Preparation and purification of PSII glycoconjugates  
PSII at avDP 15 was obtained as previously reported in literature. Purified PSII23 was reduced at the 
mannose sugar with 50 mM NaBH4 (Sigma) in 10 mM sodium phosphate buffer pH 9.0 at room 
temperature for 2 hours; the reduced PSII was purified by Sephadex G25 chromatography (G&E 
Healthcare) in water and then oxidized with 15 equivalent of NaIO4 (Sigma) in 10 mM sodium 
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phosphate buffer pH 7.2 at room temperature for 2 hours at the dark. The oxidized PSII was then 
purified by Sephadex G25 chromatography (G&E Healthcare) in water. The oxidized PSII (10 mg/ml) 
was then conjugated to carrier proteins using a stoichiometry of 4:1 (weight PSII per weight Protein) in 
200 mM sodium phosphate/1 M NaCl buffer pH 8.0, and in presence of NaBH3CN (2:1, weight PSII 
per weight NaBH3CN). The mixture was incubated for 48-72 hours at 37°C, mixing very gently with a 
magnetic stirrer. Conjugates were purified from excess of unconjugated PSII using size exclusion 
Superdex 75 chromatography (G&E Healthcare) in 10 mM sodium phosphate/10 mM NaCl buffer 
pH7.2. 
Characterization of PSII glycoconjugates 
Conjugates were characterized by SDS-PAGE using 7% Tris-Acetate gels (NuPAGE, Invitrogen). The 
samples (5 µg in term of protein) were added of 0.5 M dithiothreitol (1/5 v/v) and NuPAGE LDS 
sample buffer (1/5 v/v). The mixtures were heated at 100°C for 1 min. The gel containing loaded 
samples was electrophoresed at 45 mA in in NuPAGE Tris-Acetate SDS running buffer (20x, 
Invitrogen) and stained with Simply Blue Safe Stain (Invitrogen). 
Protein concentration was determined by MicroBCA protein assay kit (Thermo Scientific). Total 
saccharide concentration was determined by High Performance Anionic Exchange Chromatography-
Pulsed Amperometric Detection (HPAEC-PAD) analysis. Unconjugated saccharide was separated by 
SPE C4 hydrophobic interaction column (0.5 mL resin, Bioselect, Grace Vydac) and subsequently 
estimated by HPAEC-PAD analysis. 
Cloning, expression and purification of recombinant fragments 
TcdA_B2 and TcdB_GT were cloned, expressed and purified as previously described.19 Briefly, 
fragments were cloned in pet15b+ vector (N-term-His tag) using the Polymerase Incomplete Primer 
Extension (PIPE) method. The sequences coding for TcdA_B2 (residues 2303-2710 in TcdA) and 
TcdB_GT (residues 1-543 in TcdB) were amplified by PCR from the C. difficile strain 630 genomic 
DNA and the vector was amplified from the pet15b+ vector; E.coli HK100 cells were then transformed 
with vector/insert hybrids.  
PIPE method was employed to generate TcdB_GT (D270A, R273A, Y284A, D286A and D288A) 
mutant with abrogated enzymatic activity. 
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The proteins were expressed in E.coli BL21 (DE3) cells (Novagen) grown in LB. The expression of the 
protein was induced by addition of 1 mM IPTG to the culture at exponential growth phase and 
incubation for 4 hours at 25°C. 
The protein expression was checked by SDS- PAGE.19 
Recombinant TcdA_B2 and TcdB_GT were purified by Immobilized Metal Ion Affinity 
Chromatography (IMAC) and buffer exchange was performed by PD-10 desalting column (GE 
Healthcare) or by dialysis. Protein quantification was performed by BCA assay (Thermo Scientific).  
Immunization protocol 
Animal experimental guidelines set forth by the Novartis Animal Care Department were followed in 
the conduct of all animal studies. 
Groups of 8 female BALB/c mice (5-6 week old) were immunized on days 1, 21 and 35 with 2.5 µg of 
conjugated carbohydrate antigen formulated with MF59 (mixing equal volume of conjugate and MF59 
suspension) as adjuvants. All immunizations were performed by administering a 200 µl of vaccine via 
intraperitoneal route. Adjuvant alone was used for negative control groups. Sera were collected on days 
0 (before the first immunization), 34 and 49 (two weeks after the third immunization). 
ELISA assay 
Specific antibodies titers were determined 2 weeks after the third immunization by ELISA assay. For 
that purpose 96-well Maxisorp plates (Nunc, Thermo Fisher Scientific) were coated with 100 µl/well of 
2 µg/ml (protein content) PSII-HSA conjugate (prepared as previously reported23) or TcdA_B2 protein 
or TcdB_GT protein in PBS pH 7.2. Plates were incubated over night at 4°C, then washed three times 
with TPBS (0.05% Tween 20 in PBS, pH 7.4) and blocked with 100 µl/well of 3% BSA (Sigma-
Aldrich) for 1 hour at 37°C. Each incubation step was always followed by triple TPBS wash. Serum 
samples were initially diluted 1:1000 in TPBS, transferred into coated-blocked plates (200 µL) and 
serially two-fold diluted followed by 2 hours incubation at 37°C. Then 100 µl/well of 1:10000 diluted 
alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma-Aldrich) were added and left for 1 hour 
at 37°C. Visualization of bound alkaline phosphatase was performed by adding 100 µl/well of 1 mg/ml 
para-nitrophenyl-phosphate (pNPP) disodium hexahydrate (Sigma-Aldrich) in 0.5 M diethanolamine 
buffer pH 9.6. After 30 minutes of development at room temperature, the OD of each sample was 
measured at 405 nm with a microplate spectrophotometer (Biorad). Antibody titres were expressed as 
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the reciprocal of sera dilution corresponding to a cut off OD = 1.0. Each group of immunization was 
represented as the geometrical mean (GMT) of the single mouse titers. 
The statistical and graphical analysis was performed using GraphPad Prism 5 software by applying the 
Mann Whitney test for statistical analysis. 
In vitro neutralization assay 
Toxin A and Toxin B were purified from C. difficile VPI10463 strain as previously described.19 IMR-
90 human fibroblasts were obtained from American Type Culture Collection (ATCC, Rockville, MD). 
Cells were grown to 80-90% confluence in 96-well plates in EMEM (Eagle’s Minimum Essential 
Medium) with 10% fetal calf serum. The minimal doses of Toxin A and Toxin B needed to cause 100% 
rounding in 24 hours (1 CTU100) were defined as 20 ng/ml and 10 pg/ml, respectively.  For 
neutralization assay two-fold dilutions of mouse sera from 1:8 to 1:32000 were pre-incubated with 1 
CTU100 of each toxin in cell medium for 90 minutes at 37°C. Sera and toxins mixtures were then added 
to the cells and incubated for 16-18 hours before analysis. Pre-immune sera were used as negative 
controls. The endpoint titers were defined as the reciprocal of the highest dilution able to inhibit cell 
rounding. 
 
4. Conclusions  
C. difficile is considered the most important identifiable cause of healthcare-acquired diarrhea. The 
tendency of CDI to relapse and lack of efficacious preventative therapies render a vaccine highly 
recommendable. Typically, the two toxins A and B have been targeted for vaccine development. The 
surface polysaccharide PSII conjugated to CRM197 has also been proven an optimal target for a 
carbohydrate-based vaccine. In the present study we explored the feasibility of a glycoconjugate 
vaccine where the PSII saccharide was conjugated to the two protein fragments TcdA_B2 and 
TcdB_GT from toxin A and B, respectively.  
We demonstrated that TcdB_GT is a very efficient carrier for PSII, since PSII-TcdB_GT was highly 
immunogenic and induced high titers of anti-polysaccharide IgG antibodies, in a comparable manner to 
the PSII-CRM197 conjugate. On the other hand the PSII-TcdA_B2 conjugate was less efficient in 
inducing anti-PSII IgGs. Since the chemical characteristics of the two conjugates are comparable, the 
reason for this different behavior might reside in the different intrinsic ability of the two carriers to 
drive the antibody response toward the carbohydrate moiety.  
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It is important to note that conjugation to the polysaccharide does not impact the neutralizing activity of 
both TcdA_B2 and TcdB_GT. Therefore, we conclude that conjugation of C. difficile carbohydrate 
antigens to toxin fragments is a promising approach for the design of a conjugate vaccine which targets 
both surface exposed carbohydrate as well as secreted toxins. Further evaluation in suitable animal 
models is needed to fully understand the capacity of such constructs to prevent colonization and 
neutralize toxin activity. 
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Introduction 
Site-selective bioconjugation methods represent powerful tools to generate novel therapeutic proteins, 
molecular probes, targeted delivery systems and bionanomaterials.1,2 Glycosylation of proteins can 
profoundly affect the pharmacokinetics and activity of protein-based medicines.3 Glycans are poorly 
immunogenic, however conjugation to protein carriers ensures elicitation of carbohydrate specific T-
cell-dependent memory response.4 Carbohydrate-based vaccines are often produced by coupling the 
saccharides to the surface abundant lysine residues of the protein carrier, but the regioselectivity of 
conjugation is hard to achieve.  Thus, batch-to-batch variability in the immunological properties can be 
introduced.  In contrast, tyrosine residues are usually much less present and accessible than lysine 
residues, hence regioselective conjugation can be expected. We have recently developed a robust 
tyrosine-selective amination via a triazolidinone-ene reaction in tris buffer.5 The method enabled the 
creation of an anti-candidiasis vaccine through Cu(I) catalyzed azide-alkyne [3+2] cycloaddition 
(CuAAC)6,7 of a synthetic β-glucan onto specific tyrosine residues of the genetically detoxified 
diphtheria toxin CRM197. By this strategy we obtained a detailed structure-immunogenicity relationship 
of glycoconjugates with defined sugars at predetermined sites, and deciphered the contribution of the 
glycan, the linker and the attachment site on their immune properties.8  
A few carrier proteins, such as CRM197, diphtheria (DT) and tetanus toxoid (TT), are generally 
employed for licensed vaccines or candidates under clinical development.9 The use the same carriers 
for multivalent vaccines or subsequent vaccinations can in some cases interfere with the anti-
polysaccharide immune response.10-12 Therefore, the identification of novel carrier protein is a relevant 
topic for the development of the future vaccines.  
Group B Streptococcus (Streptococcus agalactiae - GBS) is a Gram positive pathogen that causes 
severe invasive neonatal infections, such as pneumonia, septicemia and meningitis.13 Of the 10 
serotypes identified on the basis of the capsular polysaccharide (CPS) structure,14,15 five (Ia, Ib, II, III, 
and V) are commonly associated with human diseases. A glycoconjugate vaccine comprising 
conjugates of PS Ia, Ib and III, which covers the majority of the infections, is currently under phase II 
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clinical trial.16, 17 After genome sequencing of GBS strains, and high-throughput expression and testing 
of a number of surface proteins by the reverse vaccinology approach,18 pilus proteins have been found 
to protect immunized mice against a lethal challenge with GBS.19,20 The conjugation of the capsular 
polysaccharides to proteins of the same antigen could be a general strategy to broaden the strain 
coverage of glycoconjugate vaccines.  
In the newly developed tyrosine-ligation we envisaged a powerful method to direct polysaccharide 
conjugation at predetermined sites of the protein, and ensure higher batch-to-batch consistency in 
comparison to classic nonspecific conjugation procedures, particularly when the protein is used with 
the dual role of antigen and carrier. 
To our surprise, preliminary attempts to conjugate high molecular weight negatively charged GBS 
polysaccharides to the tyrosine residues of CRM197 by CuAAC provided the desired glycoconjugates at 
poor yield. Conversely, condensation of 4-pentinyl lactose 421 (Figure 2) was successful, indicating that 
our method,5 which was proven very efficient which small-medium size oligosaccharides, was not 
suitable for larger polysaccharides, such as the ones from GBS.  We reasoned that the CuAAC could be 
hampered by the reduced accessibility of the catalyst to these large coupling partners.22 
We, therefore, hypothesized that strain-promoted azide-alkyne [3+2] cycloaddition (SPAAC),23-25 
which benefits of high rate of the cycloaddition bypassing the need of a catalyst26 would represent an 
optimal approach for the conjugation of this type of polysaccharides.  Herein, we report a two-step 
strategy for copper-free conjugation of defined glycans equipped with a cyclooctyne arm to 
predetermined tyrosine residues of CRM197 and GBS pilus proteins modified with a novel azide-linker, 
and its utilization for the coupling of streptococcal polysaccharides (Figure 1). Integrity of protein 
epitopes in the modified proteins was ascertained by competitive ELISA, and covalent attachment of 
protein and polysaccharide in the glycoconjugates was confirmed by immunoblot assays. The 





Figure 1. Synthesis of glycoconjugates by tyrosine-ligation copper-free azide-alkyne [3+2] cycloaddition. 
 
Results and discussion 
To develop a general strategy suitable for tyrosine directed conjugation of both well-defined glycans 
and complex polysaccharides through SPAAC (Figure 1), we initially designed and synthesized a set of 
different length sugars bearing an amine function for coupling to N-hydroxysuccinimyl ester of the 
monofluoro-cyclooctyne (MFCO)23 linker (Figure 2).  
 
 





Compounds 2-5 and 8 were prepared by standard manipulations of commercially available sugars (as 
described in SI).27 To further test our approach in the context of a convergent total synthesis of 
glycoconjugates, the β-(1→4)-chitin dimer 6 and tetramer 7 were assembled as depicted in Scheme 1. 
These structures are biologically relevant, since chitins have been found in the inner core of fungal cell 
wall28 and as part of bacterial peptidoglycan.29 The assembly of the β-(1→4)-oligoglucosamines is 
particularly challenging due to the presence of the deactivating acetamido group at the C-2 position of 
each repeating unit.30,31 Our synthesis commenced from the known thioglycoside 9,31 which was used 
as acceptor for trimethylsilyl trifluoromethanesulfonate (TMSOTf) promoted glycosylation with 11, 
obtained by levulinoylation at C-3 hydroxyl group and following conversion to phosphate donor, to 
give disaccharide 14.32  
The dimer 6, derivatized at the end terminus with an arm for conjugation, was prepared by reaction of 
14 with 3-azidepropanol in the presence of N-iodosuccinimide (NIS)/Trifluoromethanesulfonic acid 
(TfOH) and a subsequent series of deprotecting steps that include removal of N-phthalamido groups, 
reacetylation, methanolysis of the acetyl esters and final debenzylation. The assembly of the tetramer 6 
was achieved from the disaccharide acceptor 17, readily available by 3-O-develvulinoylation of 16, 
through a [2+2] convergent approach. For this purpose, the disaccharide fluoride donor 15 was 
prepared from thioglycoside 14 by treatment with diethylaminosulfur trifluoride (DAST)/N-
bromosuccinimide (NBS)33 or, alternatively, by chemoselective TMSOTf promoted glycosylation with 
phosphate donor 11 of fluoride acceptor 13, obtained from 10 by reaction with DAST/NBS succeeded 
by orthogonal removal of the 3-O-levulinoyl ester. Bis(cyclopentandienyl) Hafnium(IV) dichloride 
(Cp2HfCl2)/silver trifluoromethanesulfonate (AgOTf) promoted glycosylation of 16 with 15 yielded 
the protected tetramer 18. To our best knowledge, this represents the first example of selective 
glycosylation using phosphate and fluoride partners. Deprotection of 18, similarly to dimer 6, 




Scheme 1. Reactions leading to chitin dimer 6 and tetramer 7. Reagents and conditions: a.  Levulinic acid, DMAP, DCC, 
CH2Cl2, 91%; b. HOPO(OBu)2, NIS-TfOH, CH2Cl2, -40°C to rt, 87%; c. DAST-NBS, CH2Cl2, -10°C to rt, 80% from 10, 
65% from 14; d. H2NNH2.AcOH, CH2Cl2, 85% from 12, 94% from 16; e. TMSOTf, 9, CH2Cl2, -30°C to rt, 93%; f. 
HO(CH2)2N3, CH2Cl2, -40°C to rt, 69%; g. Cp2HfCl2-AgOTf, CH2Cl2, -10°C to rt, 55%; h. NH2CH2CH2NH2, EtOH, 60°C; 
Ac2O, MeOH; NH3, MeOH; H2, 5% Pd-C, MeOH, 64% from 16, 53% from 18. 
 
Insertion of the amine groups in GBS PSII and V for coupling with MFCO-NHS was accomplished by 
targeting 20% chemoselective periodate oxidation of the NeuAc 9,8-diol, and subsequent reductive 




Scheme 2. Modification of PSII or V. Reagents and conditions: a. NaIO4, 10 mM NaPi; b. NH4OAc, NaCNHB3, 5 mM 
NaOAc, 60-65%. 
 
Both defined glycans and polysaccharide were then coupled to MFCO active ester to deliver the 
molecules ready for strain-promoted coupling to the labeled proteins (Scheme 3). 
 
Scheme 3. Insertion of the MFCO linker on the carbohydrates.  
Reagents and conditions: MFCO-NHS, DMSO or 9:1 DMSO-H2O,  
TEA, 80-90%. 
 
For the tyrosine-directed modification of the proteins, linker 1 was designed without the phenyl group 
present in our first generation of spacers, which we have shown to induce unwanted antibodies.8 
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Incubation of CRM197 with linker 1 (prepared as described in SI), under the conditions previously 
reported,5 gave the modified protein with an average incorporation of 3.5 azides, as determined by LC-
MS analysis. As expected, MS/MS analysis of proteolytic digests showed, in agreement with our 
previous findings, that Y27, Y46, Y358 and Y380 were modified among the 18 tyrosine 
residues totally available in CRM197.5,8  
Having demonstrated that insertion of linker 1 proceeded uneventfully as reported for similar tyrosine 
modifications, we directed our attention to the GBS pilus proteins, GBS80 and GBS67. 
GBS assembles two types of pili on its surface that mediate bacterial adherence to host cells.35 Two 
pilus island (PI) variants, PI-1 and PI-2, have been described, with the latter differentiated into 
components 2a and 2b.36 GBS80 is a three domains protein, which constitutes the major component of 
GBS PI-1 pilus,37 while GBS67 is an ancillary highly conserved four domains protein of 2a pilus.38 	  
GBS80 and GB67 were modified with 1 in a fashion similar to CRM197, and an average labelling of 2 
and 3.5 tyrosine residues, respectively, was ascertained by LC-MS.  Semi-quantitative MS analysis 
of peptide digests enabled to cover 17 of the 18 tyrosine residues of GBS80 and identification of 
Y16, Y23, Y44 and Y135 as the modified sites (Table S1, SI).  Interestingly, in the case of GBS67 
36 of the 39 tyrosine residues were covered, and Y744 resulted in a higher level of 
modification, while Y282/283, Y336/337 and Y403 were modified at a lower extent (Table S2, 
SI). 
By competitive ELISA we ascertained that the modification of the tyrosine residues did not impair the 
exposition of peptide epitopes onto GBS80 or GBS67, as unmodified and modified proteins were 
comparably strong as inhibitors of the binding of polyclonal anti-protein murine sera to the 
immobilized proteins (Figure 3). 
Following our main purpose, we first developed a procedure for conjugation of the defined glycans 2-8 
with the MFCO linker installed. In spite of the moderate constant rate reported for the MFCO in 
SPAAC,23 a good progression of the reaction was observed already in 1 h by mixing the labelled 
protein at 300 µM azide concentration (~5 mg/mL protein concentration) with a 10-fold excess of 
MFCO-glycan (Figure S1). In general, overnight incubation of the labelled proteins at 200-300 µM 
azide concentration with a 2-fold excess of MFCO-glycan was sufficient to achieve complete reaction 
regardless of the sugar length (Table 1; Figures S2-S6 for SDS page electrophoresis and MALDI TOF 
MS).39 Although cycloalkynes enabling more expeditious click reactions have been recently 




Figure 3. Competitive ELISA of the binding between specific anti-protein polyclonal sera and the protein as coating reagent, 
using unmodified and labeled proteins as inhibitors. A) GBS80 and GBS80-1 are equipotent inhibitors of the binding (IC50 
= 15 and 10 µg/mL, respectively); GBS67 is the negative control. B) GBS67 and GBS67-1 are equipotent inhibitors of the 
binding (IC50 = 33 and 18 µg/mL, respectively); GBS80 is the negative control. 
 
Table 1. Conjugation of different length  oligosaccharides to the proteins 
 
Glycana 
Glycan loading  
(Coupling efficiency %) 















































a.  All glycans were coupled to MFCO-NHS prior to  
conjugation as described in SI, with the exception of 4, 
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 which was directly coupled via CuAAC;  
b. not determined. 
 
Next, we tested the optimized protocol in the conjugation of GBS PSII and V to the different proteins. 
Modified proteins (~5 mg/mL) and MFCO-activated polysaccharides were gently shacked overnight at 
different w/w ratios, as summarized in Table 2. After chromatography of the produced glycoconjugates 
on hydroxyapatite column, the amount of conjugated and unconjugated sugar in the final products was 
estimated by HPAEC-PAD (Table 2).40 Notably, when the same stoichiometry of polysaccharide and 
protein was applied, conjugation by SPAAC gave the GBS-PSII construct at higher yield in 
comparison to CuACC (36 vs 9%; Table 2, entry 2 and 3). The amount of condensed polysaccharide 
was proportional to that used in the conjugation step (Table 2, entry 3 and 4).  
 
Table 2. Characteristics of the synthesized GBS glycoconjugates 








1 PSII-Y-CRM197 3:1 1.8 < 2.8 41 
2 PSII-Y-GBS80 6:1 2.7 < 1.8 36 
3 PSII-Y-GBS80e 6:1 1.9 13.5 9 
4 PSII-Y-GBS80 1:1 1.1 < 4.5 32 
5 PSII-Y-GBS67 4:1 1.3 < 3.8 32 
6 PSV-Y-GBS80 4:1 2.2 < 5.5 37 
7 PSV-Y-GBS67 4:1 2.3 < 5.1 24 
a. Ratio of reagents used in the conjugation reaction; b. carbohydrate:protein ratio in the purified glycoconjugate; c. conjugated  and unconjugated PS in 
the purified products were estimated by HPAEC-PAD quantification of Gal for PSII adducts or GlcNAc for PSV adducts; d. determined  by micro-BCA 
quantification of purified glycoconjugate vs the starting protein; e. this conjugate was prepared by CuAAC. 
 
For instance, a 1:1 carbohydrate-protein ratio (w/w) during the coupling step (~4:1 mol MFCO/mol 
azide) was sufficient to attain the glycoconjugate PSII-GBS80 with a final glycosylation degree of 1.1 
(w/w). Incubation of polysaccharide and protein in 3-4:1 ratio (w/w) (12-16:1 mol MFCO/mol azide) 
guaranteed a higher glycosylation degree (1.8-2.3:1, w/w).   
The covalent linkage between the protein and polysaccharide was confirmed by Western blot (WB) 
analysis (Figure 4), demonstrating that only glycoconjugates were stained concomitantly by specific 
anti-protein and anti-polysaccharide murine sera, when compared to the protein, the polysaccharide and 




Figure 4. Example of immunoblot characterization of GBS glycoconjugates. a) SDS page of GBS80-Y-PSII (entry 4; Table 
1), using the labeled protein, PS and their mixture as controls; b) WB analysis with anti-protein murine sera shows staining 
for the starting protein, its mixture with the sugar and the glycoconjugate; c) WB analysis with anti-PS murine sera 
highlights staining only for the glycoconjugate, clearly confirming the covalent linkage of PS with the protein. 
 
Conclusions 
We described the development of a two-step conjugation strategy based on copper-free [3+2] 
cycloaddition of sugars modified with a cyclooctyne and proteins derivatized at the tyrosine residues 
with the novel azido-linker 1. This method was first proven efficient in the preparation of 
glycoconjugates with defined attachment point from minimal amounts of synthetic carbohydrates, 
whose preparation generally requires multistep syntheses and substantial effort.  Next, the novel 
approach was successfully applied to the preparation of glycoconjugates from GBS PSII and PSV and 
the pilus proteins GBS80 and GBS67, previously selected as vaccine antigens through the reverse 
vaccinology approach. By competitive ELISA we verified that the proteins are not affected by the 
selective ligation of the linker onto the tyrosine residues.  The covalent linkage of the saccharides and 
the protein was ascertained by immunoblot analysis. This technology appears very appealing for the 
conjugation of carbohydrate haptens to protein antigens,41 as it ensures high consistency in the 
conjugation step and easy in process MS analysis of the modified protein whose functionality needs to 
be preserved. This approach will be useful to extend the coverage of glycoconjugate vaccines. Ongoing 
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Introduction 
Gram-positive Streptococcus agalactiae or Group B Streptococcus (GBS) is a leading cause of 
invasive infections in pregnant women, newborns and the elderly people.1 Most GBS strains possess a 
capsular polysaccharide (PS) on their surface which is a major virulence factor. Ten different PS 
serotypes have been characterized, five of which are responsible for the vast majority of the disease in 
North America and Europe. GBS infection can be contracted by neonates from the maternal genital 
tract, and can result in prematurity of the newborn or bacteremia - generally pneumonia or menigitidis.2 
Therefore vaccination of pregnant women represents the best strategy for prevention of GBS infection 
in newborns.3, 4 Early in 1930s Rebecca Lancefield et al. demonstrated that polyclonal antibodies from 
rabbit sera, able to recognize PS epitopes, conferred protection against GBS infection in animal 
models.5-7 During the last two decades, plain GBS polysaccharides have been extensively studied as 
vaccines in preclinical and clinical studies.1, 2, 8 However, the first human clinical trials conducted in the 
1980s showed that the purified native PS from serotype III was not sufficient to induce a robust IgG 
response in adults.1, 9 Conjugation of poorly immunogenic microbial polysaccharides to protein 
carriers, such as the chemically detoxified diphtheria and tetanus toxin (DT and TT, respectively) or the 
genetically detoxified diphtheria toxin (CRM197), is a well-known mode to trigger an anti-carbohydrate 
T-cell-dependent memory response early in life, susceptible of boost effect.10, 11  The conjugation of 
GBS PSs to TT and CRM197 has been shown to elicit long term protection in mice.12-15 A trivalent GBS 
polysaccharide-protein conjugate vaccine composed of capsular epitopes from serotypes Ia, Ib and III 
is undergoing phase-II evaluation among pregnant women in Europe, North America and Africa.16 In 
the future it may be necessary to broaden coverage against others strains that are emerging, primarily 
GBS II and V.17 In this instance, several efforts have been focused on the identification of highly 
protective protein antigens that are present in most strains, including the non-capsulated ones. Unlike 
the conventional vaccine approaches, genome based “reverse vaccinology” has enabled the rapid 
identification of protective protein antigens.18, 19 By this approach, it has been demonstrated that a 
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combination of GBS pilus proteins, besides being important structures in bacterial adhesion and 
invasion, confers wide protection against GBS. Genome sequence analysis of GBS revealed three 
independent loci, named Pilus Island 1 (PI-1) and Pilus Island 2a and 2b (PI-2a, PI-2b) that encode 
structurally distinct pilus types, and the backbone protein of PI-1 (GBS80) was identified among the 
potential protein antigens.20, 21  
It has been observed that pre-exposure to the carrier can in some cases lead to reduction of the anti-
carbohydrate immune response against glycoconjugate vaccines (carrier epitope suppression).22 Use of 
carrier proteins alternative to DT, TT and CRM197, that are usually employed in the manufacturing of 
most the glycoconjugate vaccines currently in the market, could be a way to overcome this effect.23 
Conjugation of streptococcal polysaccharides to GBS80 pilus protein could, therefore, be an attractive 
approach to extend the vaccine coverage. 
Usually glycoconjugate vaccines are prepared by non-selective covalent coupling of the carbohydrate 
antigen to carrier protein through  -amine group or carboxyl group of K or D/E residues respectively. 
Over the recent years, methods for site selective bioconjugation are emerging.24, 25 Our group has 
recently developed a robust method for insertion of alkyne-containing bifunctional linkers onto the 
tyrosine residues of the carrier protein and subsequent condensation of glycans via copper mediated 
azide-alkyne [3+2] cycloaddition.26-28 This strategy was proven a powerful technology to establish a 
robust structure-immunogenicity relationship from anti-Candida albicans glycoconjugate prepared 
with defined sugars at predetermined Y residues.29 This two-step conjugation to tyrosine residues 
allows fast determination by LC ESI MS of the sites where the glycan coupling will be directed, thus 
ensuring a higher batch-to-batch consistency in vaccine production in comparison to the classic random 
conjugation, and to control preservation of protective protein epitopes. We have also shown that 
conjugation of high molecular weight charged GBS polysaccharides can be achieved with high 
efficiency by using a copper-free based conjugation strategy.30 Following that work, in the present 
study we explored the possibility to obtain conjugates of GBS PSII to GBS80, where the protein is 
used with the dual role of carrier and antigen. In this context, the effect on in vivo efficacy of vaccines 








Results and Discussion 
Preparation of glycoconjugates. To investigate the potential use of streptococcal pili proteins as both, 
protective antigens and carriers for GBS polysaccharides, glycoconjugates of GBS80 and PSII were 
prepared. PSII is a complex negatively charged high molecular weight polysaccharide, whose repeating 
unit is depicted in Figure 1. 
 
Figure 1. GBS CPSII repeating unit. 
Pilus protein GBS80 is composed by three domains, namely N1, N2 and N3, and constitutes the major 
component of GBS PI-1 pilus.31 The N2N3 domain, consisting of the 35 kDa C-terminal fragment, and 
its structure has been recently resolved at atomic level. As we have reported, the insertion of the 
monofluoro-cyclooctyne (MFCO) arm enables copper-free azide-alkyne [3+2] cycloaddition of the 
protein labelled with an azide linker (Scheme 1).30 This approach provided the desired 
conjugate with excellent coupling efficiency when compared to the direct reductive amination 
(Table 1).  
 






Free saccharidec   Conjugation 
efficiencyd           
GBS80/PSII 2:1 1.8    14.7% 86% 
GBS80-Y-N3/PSII 1:1 1.1 < 4.5% >95% 
a. Ratio of reagents used in the conjugation reaction; b. carbohydrate:protein ratio in the purified glycoconjugate; c. conjugated  and unconjugated PS in 
the purified products were estimated by HPAEC-PAD quantification of Gal; d. percentage of carbohydrate attached to protein in respect to the amount 
used in conjugation. 
 
Interestingly, labelling of GBS80 with the triazolidinone linker occurred at the residues Y16, Y23, Y44 
and Y135 of the N1 protein domain, as determined by LC MS of the digested peptides. This data 
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indicated that the N-terminal domain is the more flexible and accessible portion of the protein. 
Preliminary data showed that the insertion of the linker onto the N1 domain did not impair the 
recognition of the epitopes from sera generated against full GBS80.30 Therefore, we could predict that 
the protein immunogenicity was being preserved by the tyrosine-directed conjugation. 
For random polysaccharide II conjugation, regioselective NaIO4 oxidation targeting the glycerol chain 
of 20% sialic acid residues was used to generate aldehyde groups on the polymer. This material was 
used for direct conjugation of GBS80 through random reductive amination with sodium 
cyanoborohydride (Scheme 1). Alternatively, reductive amination of the foregoing aldehydes in 
presence of ammonium acetate provided the amine groups for the insertion of the N-
hydroxysuccinimide ester of the MFCO linker. This modification permitted to introduce the 
cyclooctyne enabling subsequent high efficiency coupling to the protein by copper-free click 
chemistry. Purification of the final glycoconjugates was performed by chromatography on 
hydroxyapatite, and tuning of the phosphate buffer concentration used for elution enabled to separate 
the glycoconjugate from the unconjugated polysaccharide and protein. The characteristics of the 
synthesized glycoconjugates are described in Table 1. Both Y-directed conjugation via copper-free 
click chemistry and classic reductive amination showed very good efficiency in terms of incorporated 
saccharide.  
 




Immunogenicity of the glycoconjugates. The synthesized glycoconjugates were tested in mice for 
their capability to elicit specific anti-PSII and anti-GBS80 antibodies, which can meditate 
opsonophagocytic killing (OPKA) of strains expressing the capsular polysaccharide and the protein, 
respectively, and confer protection to the offspring from GBS infection (Tables 2 and 3).  
To this end, two groups of sixteen CD-1 female mice were immunized with three subcutaneous 
injections of the prepared conjugates, with a dose of 1 µg in terms of polysaccharide and protein 
content, respectively. The animals received booster doses of the same vaccine at three and six weeks 
after the initial vaccination. The responses induced by the glycoconjugates were compared to the 
unconjugated PSII, when the protein was evaluated as carrier for the sugar, and to GBS80, when it was 
tested as antigen. The adjuvant alone was the negative control.  
Following ELISA analysis of the elicited antibodies, the functionality was assessed by in vitro killing-
based opsonophagocytosis assay (OPKA).32 This is a well-established analysis that mimics the in vivo 
process of bacterial killing by host effector cells, following opsonization by specific antibodies.32  In 
addition, it has been demonstrated that passive protection of mice by sera from individuals immunized 
with GBS polysaccharide-based vaccines correlate with high functional antibody titers measured by 
OPKA, suggesting that this assay can constitute a viable surrogate of the effectiveness of a GBS 
vaccine.33 By using the strain 5401, which is heavily coated by PSII, while Pl-1 proteins are very 
poorly expressed, the functional activity of the antibodies against bacteria producing the polysaccharide 
was measured. Vice versa, the strain CHO1 was used to assess the functionality against strains which 
do not express PSII but GBS80 only. 
The capability to transfer functional antibodies from the vaccinated female mice to the offspring was 
finally tested by survival model.20, 21 To distinguish the effectiveness of the conjugated PSII and the 
protein as vaccine antigens, pups were challenged 35 days after the third immunization with a killing 
dose of either GBS strain 5401 or CHO1, respectively. The results of these in vivo experiments in 
correlation with the measured IgG and OPKA titers are shown in Tables 2 and 3. 
 
Table 2. Evaluation of GBS80 as carrier for PSII at 1 µg polysaccharide dose. 
Glycoconjugate 
Anti PSII 









PBS <10 <30 6/59 10 
GBS80/PSII 4956 (1273 ; 19299) 2443 36/60 60 
GBS80-Y-N3/PSII 384 (97 ; 1523) 2327 68/69 98 




ELISA analysis of sera generated at equal dose of carbohydrate hapten indicated that, while PSII non-
covalently linked to GBS80 did not produce any anti-carbohydrate antibody response, both the 
glycoconjugates prepared by random conjugation and Y-directed ligation induced specific anti-PSII 
IgGs (Table 2). The antibody response elicited by GBS80/PSII was approximatively 10 fold higher 
than that achieved by vaccination with GBS80-Y-N3/PSII.  This effect could be due to the presence of 
non-responder mice in the group immunized with the latter vaccine. Importantly, the sera from mice 
vaccinated with the two conjugates showed comparable killing of the 5401 strain, which translated into 
an effective protection of the pups from a lethal dose of 5401 strain. These findings, therefore, 
highlighted that the protein GBS80 can efficiently function as carrier for PSII, regardless of the 
conjugation chemistry. A higher protection was observed in this model by vaccination with GBS80-Y-
N3/PSII in comparison to GBS80/PSII. 
 
Table 3. Evaluation of GBS80 as antigen at 1 µg protein dose. 
Glycoconjugate 
Anti GBS80 








PBS 10 <30 28/80 35 
GBS80 3099 (69 ; 137225) 276 35/60 58 
GBS80/PSII 775 (83 ; 7240) 676 30/60 50 
GBS80-Y-N3/PSII 3111 (426 ; 22705) 282 49/70 70 
 
When the glycoconjugates were compared at the same protein dose (Table 3), we measured by ELISA 
analysis anti-protein IgG antibodies at statistically comparable levels to those elicited by the 
unconjugated GBS80 in the sera obtained from both the constructs. Interestingly, the conjugate 
synthesized by Y-selective coupling raised four fold higher anti-protein titers than the counterpart 
prepared by reductive amination at K. This result could be explained with the more homogenous 
conjugation of the polysaccharide achieved through the Y-directed ligation or, alternatively, with the 
slightly lower glycosylation degree of this conjugate. In accordance with the IgG levels, the OPKA 
titers induced by the two conjugates against the CHO1 strain were comparable each other and to the 
GBS80 alone. The generated antibodies were also effective in inducing good protection of the offspring 
from a lethal infection with COH1 strain, with again a moderately higher protection for the vaccination 
with GBS80-Y-N3/PSII. 
Overall, these results clearly demonstrated that GBS80 can be conjugated to PSII and function as 
carrier while maintaining its properties of antigen.  The two constructs prepared by diverse conjugation 
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approaches are both effective in raising functional antibodies against PSII and GBS80 expressing 
strains. Despite the relatively high variability of the animal model, a moderately higher percentage of 
survival seems to be conferred by vaccination with GBS80-Y-N3/PSII in respect to GBS80/PSII (98 
vs. 60% for 5401; 70 vs. 50% for CHO1). 
 
Analysis of epitope recognition. The recognition of polysaccharide and protein epitopes in the two 
conjugates was further analyzed by competitive ELISA (Figure 3). When the binding of specific anti-
PSII polyclonal sera to HSA-PSII conjugate was inhibited by GBS80-Y-N3/PSII and GBS80/PSII, 
both the constructs exhibited a half maximal inhibitory concentration (IC50) comparable to the 
unconjugated PSII (Figure 3A). Intriguingly, inhibition of the protein recognition from anti-GBS80 
sera showed that the conjugates were better inhibitors than the protein itself (Figure 3B).  
 
 
Figure 3. a) Competitive ELISA of anti-PSII polyclonal sera generated from mice immunized with PSII conjugated to a 
non-pilus protein, using HSA-PSII as coating reagent. GBS80-Y-N3/PSII and GBS80/PSII are compared PSII as inhibitors. 
b)  Competitive ELISA of anti-GBS80 polyclonal sera using the protein as coating reagent. GBS80-Y-N3/PSII and 
GBS80/PSII are compared to the protein, its mixture with PSII, and a conjugate prepared with shorter PSII fragments 
conjugated to GBS80. 
We reasoned that this behavior could be due to the multivalent presentation of different GBS80 units 
along one polysaccharide chain. To test this hypothesis we reduced PSII into fragments with an average 
degree of polymerization (aDP) of 40 units by controlled partial N-deacetylation followed by nitrous	  
acid	  deamination.34 The aldehyde of the generated 2,5-­‐anhydro-­‐D-­‐mannose	  residue	  was	  coupled	  to	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GBS80	  by	  reductive	  amination	  (Scheme	  S1,	  SI).	  The	  resulting	  glycoconjugate,	  presenting	  shorter	  
PSII	  fragments	  around	  one	  protein	  core,	  induced	  inhibition	  very	  similar	  to	  the	  plain	  GBS80.	  	  This	  
clearly	   proved	   that	   the	   stronger	   inhibition	   of	  GBS80-Y-N3/PSII and GBS80/PSII	   conjugates	   in	  
respect	   to	   GBS80	   was	   remarkably	   affected	   by	   the	   protein	   presentation.	  Overall, these findings 
corroborated the observation that polysaccharide and protein epitopes are well-preserved in both the 
constructs.  
  
Analysis of anti-linker antibodies. Rigid rings have been found to generate unwanted anti-linker. We 
have previously shown that in our first generation of linkers where a phenyl and a triazole ring were 
concomitantly present, these antibodies were predominantly addressed to the first one. In any case, the 
anti-glycan response was not affected by these antibodies.35 Hence, we were interested to evaluate the 
presence of antibodies directed to the neoepitope generated by condensation of the monofluoro-
cyclooctyne and the azide linker during the copper-free click chemistry reaction. To this end, a 
competitive ELISA, using the conjugate GBS80-Y-N3/PSII as coating reagent and the corresponding 
anti-serum was carried out (Figure 4).  
 
Figure 4. Competitive ELISA of anti-GBS80-Y-N3/PSII sera 
using GBS80-Y-N3/PSII as coating reagent. GBS80/PSII and 
its mixture with a conjugate CRM197-Y-N3/MenY, containing 
the MFCO linker, were compared as inhibitors. GBS80, PSII 




While GBS80-Y-N3/PSII efficiently inhibited the binding of the sera, conjugate GBS80/PSII did not 
fully inhibit the binding to the conjugate made by the copper-free click chemistry. In contrast, the 
mixture of GBS80/PSII with a CRM197-Y-N3/MenY conjugate, presenting in common with GBS80-Y-
N3/PSII the linker portion included between the modified Y residue of the protein and the oxidized 
sialic acid of the oligosaccharide (Figure 2), showed complete inhibition. This suggested that anti-
linker antibodies were present in serum from construct GBS80-Y-N3/PSII.  
The level of antibodies directed to neoepitopes generated during the coupling reactions was further 
determined by ELISA analysis of the anti-glycoconjugate sera against a series of constructs presenting 
the oxidized sialyl residue produced during the random conjugation of PSII to GBS80 (Figure 5A), and 
the condensed cyclooctene-triazole system originated by the copper-free click chemistry (Figure 5C). 
For the preparation of the coating reagents, a tetrasaccharide [α-D-Glcp(1 4)-α-D-NeuNAc-(2 6)]2 
fragment from meningococcal serogroup Y (MenY) capsular polysaccharide was employed. This 
polymer has only the terminal end sialyl moiety in common with GBS polysaccharide.  By doing so, 
we could roll out in the analysis of the sera any interference from the carrier and the other sugar 
residues. An additional reagent was used to measure antibodies directed to the triazole ring generated 
by the azide-alkyne [3+2] cycloaddition (Figure 5B). This comparative analysis evidenced that the 
presence of relatively low level of anti-linker IgGs which were primarily directed against the 
cyclooctene, rather than the triazole ring. Most importantly, the anti-linker antibodies do not impair the 




Figure 5. ELISA analysis of anti-linker antibodies using pooled polyclonal sera from mice vaccinated with GBS conjugates 
using as coating reagents: a) MenY tetramer directly coupled to CRM197; b) the triazole ring generated on BSA; c) MenY 
tetramer modified with the MFCO linker and condensed to CRM197 labeled with the azide linker. 
 
In conclusions, we have shown that the tyrosine-directed conjugation via copper-free click chemistry 
represents an excellent strategy to attach large polysaccharides to protein antigens, enabling to target 
predetermined site and to ensure high reproducibility in the conjugate formation.(30) This approach 
permits easy and fast assessment of preservation of the protein epitopes prior to polysaccharide 
conjugation.(30) In the present study we compared two conjugates prepared from GBS type II 
polysaccharide and GBS80 pilus protein through a classic random conjugation and the recently 
developed Y-directed ligation, respectively. We found that both the constructs showed a good 
capability to elicit in vivo anti-carbohydrate and anti-protein functional antibodies that induce 
opsonophagocitosis in strains expressing exclusively PSII or GBS80. In addition, the two 
glycoconjugates were both effective in protecting new born mice against GBS infection following 
vaccination of the mothers. The conjugate made by the tyrosine ligation via copper free chemistry 
generated relatively low levels of anti-linker antibodies that, however, do not affect the anti-
polysaccharide and anti-protein immune responses. By contrast it conferred moderately higher 
protection against strains expressing PSII or GBS80 than the counterpart prepared by random 
conjugation at lysine residues. These results clearly demonstrated that GBS80 pilus protein can be used 
as carrier for PSII polysaccharide while maintaining its properties of protein antigen. Furthermore, 
these findings highlight that protein antigens selected by “reverse vaccinology” can be combined with 
capsular polysaccharides through appropriate conjugation chemistries that preserve the protein epitopes 
to create vaccines with broader coverage. This approach is expected to lead to significant 
advancements towards the next generation of rationally designed glycoconjugate vaccines.  
 
Methods 
Bacterial strains. GBS serotype II strain 18RS21 was obtained from Dennis Kasper (Harvard Medical 
School, Boston, MA). The purification process was based on previously described procedures.36 Briefly, 
the bacterial pellet was recovered by centrifugation at 4,000 rpm for 20 min and incubated with 0.8 N 
NaOH at 37 °C for 36 h. After centrifugation at 4,000 rpm for 20 min, 1 M Tris buffer (1:9, v/v) was 




GBS80 expression. Pilus protein was expressed in E. coli by a plasmid vector derived from pET24b+ 
allowing the expression of the protein GBS 80 from S. agalactiae. The clone has been obtained by 
recombinant DNA techniques. The DNA fragment coding for amino acids 38-520 of GBS 80 from S. 
agalactiae strain 2603/VR was introduced in the plasmid pET24b+ for inducible expression. 
  
Protein modification. Similarly as we reported in literature,30 to the protein (0.001 µmol) in Tris 0.5 M 
pH 7.4 (67 µL) at 4°C was added four portions of 4-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-3H-
1,2,4-triazole-3,5(4H)-dione (0.25 µL, 0.005 µmol) in acetonitrile every minute (total of 20 
equivalents).  The mixture was agitated at 4°C for 30 minutes.  The mixture was desalted and buffer 
exchanged to PBS pH 7.4 two times using Zeba 7K MW cut off spin columns.   
 
Polysaccharide modification 
Periodate oxidation of PSII. Oxidation was targeted to 20% of sialic acid residues.(35) GBS type II 
PS (100 mg) was stirred with 151 µL 0.1M of sodium periodate in 9.8 mL of 10 mM sodium phosphate 
buffer in the dark, for 2 h at RT. The mixture was purified by tangential flow filtration (Sartocon 10kD 
filter).  
For the preparation of GBS80-PSII glycoconjugate through random chemistry at lysine, the oxidized 
polysaccharide (20 mg)  was dissolved in a 200 mM/NaCl 2M Sodium Phosphate buffer pH 7.2 and 
mixed to the protein (10 mg) with a final concentration of PSII of 4 mg/mL and for GBS80 2 mg/mL. 
For conjugation of PSII to tyrosine modified GBS80, the following procedure was followed. The 
oxidized PS (50 mg) dissolved in H2O milli-Q at a concentration of 5 mg/mL, was subjected to 
reductive amination by treatment with ammonium acetate (5.5 g) and sodium cyanoborohydride (1 g). 
After incubation for 5 days at 37°C, the crude mixture was filtered by Tangential Flow Filtration 
(TFF,Sartocon 10kDa filter). Quantification of polysaccharide and amino groups were performed by 
colorimetric assays. Partially aminated polysaccharide (30 mg, corresponding to 4.5 × 10-3mmol of 
oxidized sialic acid) was dissolved in 3 mL of DMSO, MFCO-N-hydroxysuccinimide 
(Berry&Associates, 10 equiv) and 50 µL of triehtylamine were added. Reaction was stirred for 3 h at 
RT. The crude was precipitated and washed (8 × 30 mL) in EtOAc at 4°C in order to remove the excess 
of unreacted linker. Then the PS was lyophilized and sialic acid was quantified by colorimetric assay. 
Modified GBS80 (3.5 mg) and activated polysaccharide (3.5 mg) were mixed in PBS at pH 7.2 and 
incubated overnight at RT. Conjugation was monitored by SDS-PAGE 3-8% of polyacrylamide in Tris 
Acetate. The conjugates were purified by a CHTTM hydroxyapatite column (Biorad laboratories). In the 
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first step of purification, unreacted protein was removed by elution with 2 mM sodium phosphate pH 
7.2 (90 mL, 1 mL/min) followed by 400 mM sodium phosphate pH 7.2 (90 mL, 1 mL/min). Then the 
conjugate was purified from free polysaccharide by another run on the same column with 2 mM 
sodium phosphate /550 mM NaCl pH 7.2 (50 mL, 0.5 mL/min), 10 mM sodium phosphate pH 7.2 (50 
mL, 1 mL/min), 35 mM sodium phosphate pH 7.2 (40 mL, 1 mL/min), 400 mM sodium phosphate pH 
7.2 (40 mL, 1 mL/min). The conjugate is detected by measuring UV absorption at 215 nm, 254 nm and 
280 nm. Protein content in the purified glycoconjugates was determined by micro-BCA (Thermo-
scientific).  
 
Total saccharide was quantified by HPAEC-PAD. A standard sample with five increasing 
concentrations of Gal ranging between 0.2 and 4.0 ug/mL (as saccharide powder/mL), was prepared for 
building a calibration curve. Two GBS PSII samples were prepared targeting final concentrations in the 
calibration curve range. The reference and analytical samples for Gal were prepared in 4 M 
trifluoroacetic acid, incubated at 100 °C for 2 h, dried under vacuum (SpeedVac Thermo), and 
suspended in water. All analytical samples were filtered with 0.45 µm Acrodisc (Pall) filters before 
analysis. HPAEC-PAD analysis was performed with a Dionex ICS3000 equipped with a CarboPac 
PA1 column (4 x 250 mm; Dionex) coupled with PA1 guard to column (4 x 50 mm; Dionex). Samples 
(50 µL injection volume) were run at 1 mL/min, using isocratic elution with 24 mM NaOH, followed 
by a washing step with 0.5 M NaOH. The effluent was monitored using an electrochemical detector in 
the pulse amperometric mode with a gold working electrode and an Ag/AgCl reference electrode. A 
quadruple-potential waveform for carbohydrates was applied.  Unconjugated saccharide was separated 
by SPE C4 hydrophobic interaction column (0.5 mL resin, Bioselect, Grace Vydac, Columbia, MD, 
USA) and subsequently estimated by HPAEC-PAD analysis. The resulting chromatographic data were 
processed using Chromeleon software 6.8 (Dionex). 
 
Preparation of PSII-HSA for ELISA coating. To HSA (Sigma), at a concentration of 10 mg/mL in 
100 mM MES (Sigma) buffer pH 5, EDAC (1.5 equiv relative to HSA carboxylic groups) was added, 
and the mixture was gently mixed to allow complete solubilization; then, ADH (13.4 equivrelative to 
HSA carboxylic groups) was added to the solution. The reaction was kept under gently stirring for 1 h 
at RT. Next, the reaction was quenched by adding 1/6 of the reaction volume of 400mM sodium 
phosphate buffer, pH 7.2.  
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The conjugation reaction was performed at GBS PSII concentration of 5 mg/mL in 100mM MES/250 
mM NaCl buffer pH 5.EDAC (1:1, mol PS/mol EDAC) and the SulfoNHS (1:1, mol PS/mol 
SulfoNHS) were added to GBS PSII solution. 
After the reageents were dissolved, HSA-ADH (2:1 protein/polysaccharide w/w) was added and the 
reaction was incubated at RT under gently stirring for 12-15 h, at which time the reaction was 
quenched by adding 1/5 of the reaction volume of 400mM NaPi buffer pH 7.2. The crude reaction was 
purified by size-exclusion chromatography (SEC) on a Sephacryl S400 resin (G&E Healthcare). The 
chromatographic step was performed on Akta TM system (G&E Healthcare) at 2 mL/min flow rate, 
detecting the conjugate by measuring UV absorption at 215 nm, 254 nm and 280 nm. 
 
Preparation of conjugate GBS80/PSII (aDP40). For the depolymerization of PSII, 10 mg of 
polysaccharide were dissolved in 5 mL of 0.5 M of NaOH and stirred at 70° C. After 6 h the solution 
was cooled, 0.5 mL of acetic acid and 1 mL of a solution 5% of nitrous acid were added and stirred at 
4°C for 2 h. Then the mixture was desalted on a G-25 column (Sephadex G-25 GE Healthcare). For the 
conjugation reaction to GBS80, 8.3 mg of depolymerized PSII were dissolved in 10 mM sodium 
phosphate buffer pH 7.2  were added to 2.5 mg of GBS80 in a solution with a final concentration of 
10mg/mL in protein. Then 8.3 mg of NaBCNH3 were added to the solution and incubated O.N. at R.T. 
Conjugation was monitored by SDS-PAGE 4-8% of polyacrylamide in MOPS. Unreacted saccharide 
was removed by 10 cycles of filtration with Vivaspin (cut-off  30 KDa) 
 
Periodate oxidation of MenY DP2. MenY DP2 was obtained by controlled acidic hydrolysis of MenY 
polysaccharide and purifications of different size oligosaccharide by anionic exchange chromatography 
on Mono Q column as described in literature.37 50% of sialic acid residues were targeted for oxidation. 
MenY DP2 (100 mg) was stirred with 491 µL 0.1M of sodium periodate in 9.5 mL of 10mM sodium 
phosphate buffer in the dark, for 2 h at RT. The mixture was purified by gel filtration chromatography 
on a Sephadex G-10 column (G&E Healthcare) using 10 mM NaCl pH 7.2 as elution buffer (190 mL, 
1mL/min). Subsequently reductive amination and linker insertion was performed with the same 
conditions reported for GBS PSII. CRM197 Modified at tyrosine residues (CRM197-Y-N3) was prepared 
as described above. 
Conjugation of CRM197-Y-N3 to modified MenY DP2. to 1.5 mg of protein (2.5 × 10-5 mmol) in 10 
mM of sodium phosphate buffer pH 7.2, the saccharide (2.1 mg, 60 eq) was added at a final 
concentration of 2 mg/mL in term of protein. The mixture was incubated overnight at RT. Conjugation 
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was monitored by SDS-PAGE 4-8% of polyacrylamide in MOPS. Unreacted saccharide was removed 
by 10 cycles of filtration with Vivaspin (30 KDa MW cut off). The loading of saccharide was 
determined by MALDI-TOF MS analysis (Bruker Daltonics). 
 
Immunogenicity of conjugates in mice. Protocols were approved by the Italian Ministry of Health. 
Animal experimental guidelines set forth by the Novartis Animal Care Department were followed in 
the conduct of all animal studies. Two groups of 8 CD-1 mice were immunized by intraperitoneal 
injection of 1 µg in polysaccharide or in protein content of each glycoconjugate using alum hydroxide 
as adjuvant. Alum hydroxide, GBS80 and the mixture of GBS80 and PSII were used as controls. Mice 
received the vaccines at days 1, 21 and 35. Sera were bled at days 1, 35 and 49.  
 
Challenge and survival protocol. The protective efficacy of GBS conjugates was measured by the 
maternal immunization-neonatal mouse challenge model of GBS infection. At day 35 a male mouse 
was added to the female mice groups. Infants were challenged with a lethal dose 90% of GBS within 
48 h of life. Newborns were monitored for 4 days and after they were sacrificed.  
 
ELISA. Direct enzyme-linked immunosorbent assay titers of PS-specific and protein antibody were 
determined using as coating reagents PSII-HAS, GBS80 or constructs with different linkers. Microtiter 
plates (NUNC Polysorp; Nalge Nunc International Corp., Rochester, NY) were coated by adding 100 
µL per well of coating reagent (1-1.5 µg/mL) in PBS 1x pH 7.2. The plates were incubated overnight at 
4°C and were washed with PBS containing 0.05% Tween 20 (PBS-T) then blocked with 0.5% bovine 
serum albumin in PBS for 1.5 h at 37°. The wells were then filled with 100 µL of serum at dilution 
1:400 in PBS and incubated at 37°C for 1h. After 3 washes, 100 µL for well of peroxidase-labeled goat 
anti-mouse was added (Sigma-Aldrich) and plates incubated for 1.5 h at 37°C. The plates were again 
washed 3 times with PBS-T and finally 100 µL of peroxidase substrate (1 µg/mL in diethanolamine pH 
9.8) was added to each well, and following incubation of the plates for 30 min at room temperature. 
The reaction was stopped by the addition of 100 µL of a solution of EDTA 7% and the plates were read 
immediately at 405 nm.  
 
Competitive ELISA. 96-well Microtiter plates (NUNC Polysorp; Nalge Nunc International Corp., 
Rochester, NY) were coated by adding 100 µL per well of GBS80 protein (1.5 µg/mL) in PBS 1x pH 
7.2. The plates were incubated overnight at 4°C and were washed three times with PBS containing 
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0.05% Tween 20 (PBS-T) then blocked with 0.5% bovine serum albumin in PBS for 1.5 h at 37°. A 
pool of antiserum versus GBS80 (dilution 1:1500 in PBS 1x pH 7.2)  were incubated 15 minutes at RT  
with different concentrations of the protein used as inhibitor in a final volume of 100	  µL and then 
transferred into coated plates. After 2 h of incubation at 37°C, plates were washed three times and of 
peroxidase-labeled goat anti-mouse diluted 1:10000 (100 µL for well, Sigma-Aldrich) was added and 
incubated for 1.5 h at 37°. The plates were again washed 3 times with PBS-T and finally peroxidase 
substrate (100 µL of a 1 µg/mL solution in diethanolamine pH 9.8) was added to each well, and 
following incubation of the plates for 30 min at room temperature. Then the plates were read 
immediately at 405 nm. The statistical and graphical analysis was performed using GraphPad Prism 6 
software. 
 
Opsonophagocytosis killing assay (OPKA). The functional activity of the sera was determined in 
OPKA assay. HL-60 cells were grown in RPMI 1640 with 20% fetal calf serum. Incubation was at 37 
°C with 5% CO2. HL-60 cells were differentiated to neutrophils with 0.78% dimethylformamide 
(DMF) and after 4-5 days  are used as source of phagocytes. 
Serum antibodies serially diluted in HBSS red were mixed with 6 ×104 CFU per well of GBS type II 
strain 5401 cells or type III strain COH1. HL-60 cells (2 × 106 cell/well) and rabbit complement 
(diluted at 2-10% in water) were added and incubated at 37°C for 1 h under shaking. Before (T0) and 
after (T60) the incubation, the mixtures were diluted and plated in blood agar plates. (NUNC Polysorp; 
Nalge Nunc International Corp., Rochester, NY) Each plate was then incubated overnight at 37°C with 
5% of CO2 counting CFUs the next day. OPA titer was expressed as the reciprocal serum dilution 
leading to 50% killing of bacteria and the % of killing is calculated as follow: Killing% : (T0-T60)\T0  
Where T0 is the mean of the CFU counted at T0 and T1 is the average of the CFU counted at T60 for 
the two replicates of each serum dilution. 
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Glycoconjugate vaccines are among the safest and most efficacious vaccines developed during the last 
30 years. They are a potent tool for prevention of life-threating bacterial infectious disease like 
meningitis and pneumonia1.  
 
The weak immunogenicity of polysaccharides, T-cell independent antigens, can be increased after their 
conjugation to protein carrier; with this strategy a glycoconjugate induced a T-cell response (TD) 
already early in life which leads to immunological memory and boosting of the response by further 
doses of the vaccine2.  
 
In the context of glycoconjugate vaccines, with saccharide antigen (B-cell epitope) coupled to a protein 
carrier (T-cell epitope), the development of more defined vaccines to improve glycoconjugate design 
has been investigated.  
A first study was directed to develop a two-step conjugation strategy based on copper-free [3+2] 
cycloaddition of sugars modified with a cyclooctyne and proteins derivatized at the tyrosine residues 
with the novel azido-linker. This method was first proven fast and highly efficient in the preparation of 
glycoconjugates with defined attachment point from minimal amounts of synthetic carbohydrates, 
whose preparation generally requires multistep syntheses and substantial effort.  Next, the novel 
approach was successfully applied to the preparation of glycoconjugates from GBS PSII and the pilus 
protein GBS80. By competitive ELISA we verified that the protein is not affected by the selective 
ligation of the linker onto the tyrosine residues.  The covalent linkage of the saccharides and the protein 
was ascertained by immunoblot analysis. This technology appears very appealing for the conjugation of 
carbohydrate haptens to protein antigens3, as it ensures high consistency in the conjugation step and 
easy in process MS analysis of the modified protein whose functionality needs to be preserved.	  
 
In the second study, by comparing two conjugates prepared from GBS type II polysaccharide and 
GBS80 pilus protein through a classic random conjugation and the recently developed Tyr-directed 
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ligation, respectively, we found that both the constructs showed comparable capability to elicit in vivo 
anti-carbohydrate and anti-protein functional antibodies that induce opsonophagocitosis in strains 
expressing exclusively PSII or GBS80 proteins. In addition, the two glycoconjugates were both 
effective in protecting new born mice against GBS infection following vaccination of the mothers. The 
conjugate made by the tyrosine ligation via copper free chemistry generated relatively low levels of 
anti-linker antibodies that do not impair the anti-polysaccharide immune response. The protection 
conferred to the dams was higher than that achieved by random conjugation. These results clearly 
demonstrated that GBS80 pilus protein can be used as carrier for PSII polysaccharide while 
maintaining its properties of protein antigen. These findings highlight, for the first time, that GBS 
polysaccharide haptens and protein antigens selected by “reverse vaccinology” can be combined to 
extend the current trivalent GBS vaccine under clinical trial. This approach is expected to lead to 
significant advancements towards the next generation of glycoconjugate vaccines. The Tyr-directed 
conjugation via copper-free click chemistry represents an excellent strategy to attach large 
polysaccharides to protein antigens, enabling fine tuning of the conjugation chemistry. This approach 
permits easy and fast assessment of preservation of the protein epitopes prior to polysaccharide 
conjugation. 
In conclusion, the PhD work has given a contribution to improve the glycoconjugate vaccine design, by 
preparing more defined structures able to maintain their immunogenicity and using pili proteins in a 
double role of antigens and carrier 
 
In another study the surface polysaccharide PSII of C. difficile conjugated to CRM197 has also been 
proven an optimal target for a carbohydrate-based vaccine. We explored the feasibility of a 
glycoconjugate vaccine where the PSII saccharide was conjugated to the two protein fragments 
TcdA_B2 and TcdB_GT from toxin A and B, respectively. We demonstrated that TcdB_GT is a very 
efficient carrier for PSII, since PSII-TcdB_GT was highly immunogenic and induced high titers of anti-
polysaccharide IgG antibodies, in a comparable manner to the PSII-CRM197 conjugate. On the other 
hand, the PSII-TcdA_B2 conjugate was less efficient in inducing anti-PSII IgGs. Since the chemical 
characteristics of the two conjugates are comparable, the reason for this different behavior might reside 
in the different intrinsic ability of the two carriers to drive the antibody response toward the 
carbohydrate moiety. It is important to note that conjugation to the polysaccharide does not impact the 







1. Costantino,P.; Rappuoli, R.; Berti, F.  The design of semi-synthetic and synthetic 
glycoconjugate vaccines , Expert Opin. Drug Discov.2011, 6 (10), 1045-1066  
 
2. Avery, O.T.; Goebel, W.F. Chemo-immunological studies on conjugated carbohydrate-proteins : 
Immunological specificity of synthetic sugar-protein antigens. J Exp Med,  1929, 50, 533-50. 
 
3. Adamo, R.; Berti, F.; Hu, Q.-Y., Cycloalkyne derivatized saccharides. From PCT Int. Appl. 

























List of Publications 
 
Nilo A, Allan M, Brogioni B, Proietti D, Cattaneo V, Crotti S, Sokup S, Zhai H, Margarit I, Berti F, Hu 
QY, Adamo R: Tyrosine-Directed Conjugation of Large Glycans to Proteins via Copper-Free Click 
Chemistry; Bioconjug Chem. 2014 Nov 21 
 
Morelli L, Cancogni D, Tontini M, Nilo A, Filippini S, Costantino P, Romano MR, Berti F, Adamo R, 
Lay L: Synthesis and immunological evaluation of protein conjugates of Neisseria meningitidis X 
capsular polysaccharide fragments; Beilstein J Org Chem. 2014 Oct 13;10:2367-76 
 
Adamo R, Nilo A, Harfouche C, Brogioni B, Pecetta S, Brogioni G, Balducci E, Pinto V, Filippini S, 
Mori E, Tontini M, Romano MR, Costantino P, Berti F: Investigating the immunodominance of 
carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C 
meningococcal disease; Glycoconj J. 2014 Dec;31(9):637-47 
 
Romano MR, Leuzzi R, Cappelletti E, Tontini M, Nilo A, Proietti D, Berti F, Costantino P, Adamo R, 
Scarselli M; Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface 
polysaccharide preserve their neutralizing activity; Toxins (Basel). 2014 Apr 22;6(4):1385-96 
 
Gao Q, Tontini M, Brogioni G, Nilo A, Filippini S, Harfouche C, Polito L, Romano MR, Costantino P, 
Berti F, Adamo R, Lay L: Immunoactivity of protein conjugates of carba analogues from Neisseria 
meningitidis a capsular polysaccharide; ACS Chem Biol. 2013 Nov 15;8(11) 
 
Adamo R, Nilo A, Castagner B, Boutureira O, Berti F and Bernardes G J L: Synthetically defined 











I would like to thank the people who supported me during these three years: my parents and 
my family, my girlfriend Sabrina and her family, my friends “I Fernandelli” and Mario, to whom 
this work is dedicated. 
 
In particular I must sincerely thank my supervisor Roberto, for guiding me and having followed 
me constantly in the realization of the doctoral thesis. I learned a lot from him both 
scientifically and humanly. 
 
Thanks to all the fantastic friends that I met in Siena and all my lab’s colleagues.   
 
Alberto 
